MDxHealth (MDXH) 20-F 25 Apr 22 2021 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2021shares
Document Information Line Items
Entity Registrant Name	MDXHEALTH SA
Trading Symbol	MDXH
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	155,969,226
Amendment Flag	false
Entity Central Index Key	0001872529
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-40996
Entity Incorporation, State or Country Code	C9
Entity Address, Address Line One	Zone Industrielle des Hauts-Sarts
Entity Address, Postal Zip Code	4040
Entity Address, City or Town	Herstal
Entity Address, Country	BE
Title of 12(b) Security	Ordinary shares, no par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	BDO Réviseurs d’Entreprises
Auditor Location	Zaventem, Belgium
Auditor Firm ID	1432
Business Contact
Document Information Line Items
Entity Address, Address Line One	15279 Alton Parkway
Entity Address, Postal Zip Code	92618
Entity Address, City or Town	Irvine
Entity Address, Country	CA
Contact Personnel Name	Michael McGarrity
Entity Address, Address Line Two	Suite 100
City Area Code	+1 949
Local Phone Number	812-6979

Consolidated statement of profi

Consolidated statement of profit or loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Profit or loss [abstract]
Services	$ 21,937	$ 18,064	$ 11,443
Licenses	250	250	250
Royalties and other revenues	52	146	92
Revenues	22,239	18,460	11,785
Cost of goods & services sold	(11,675)	(10,416)	(11,755)
Gross profit	10,564	8,044	30
Research and development expenses	(6,673)	(4,543)	(8,997)
Selling and marketing expenses	(17,744)	(16,752)	(17,809)
General and administrative expenses	(14,149)	(13,990)	(15,196)
Other operating income, net	1,161	118	(1,197)
Operating loss	(26,841)	(27,123)	(43,169)
Financial income	11	4	10
Financial expenses	(2,172)	(1,543)	(516)
Loss before income tax	(29,002)	(28,662)	(43,675)
Income tax	0	0	575
Loss for the year	$ (29,002)	$ (28,662)	$ (43,100)
Loss per share attributable to parent
Basic and diluted (in Dollars per share)	$ (0.24)	$ (0.34)	$ (0.69)

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statement of Comprehensive Income [Abstract]
Loss for the year	$ (29,002)	$ (28,662)	$ (43,100)
Other comprehensive income (loss)
Exchange differences arising from translation of foreign operations	264	(383)	253
Total other comprehensive income (loss)	264	(383)	253
Total comprehensive loss for the year (net of tax)	$ (28,738)	$ (29,045)	$ (42,847)

Consolidated Statement of Finan

Consolidated Statement of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	$ 3,448	$ 5,058
Property, plant and equipment	1,671	973
Right-of-use assets	3,347	2,734
Total non-current assets	8,466	8,765
Current assets
Inventories	1,911	2,324
Trade receivables	4,582	3,771
Prepaid expenses and other current assets	1,615	1,043
Cash and cash equivalents	58,498	15,953
Total current assets	66,606	23,091
TOTAL ASSETS	75,072	31,856
EQUITY
Share capital	128,454	76,716
Issuance premium	153,177	136,349
Accumulated deficit	(244,302)	(215,300)
Share-based compensation	10,607	9,385
Translation reserve	(1,037)	(1,301)
Total equity	46,899	5,849
Non-current liabilities
Loans and borrowings	7,651	10,279
Lease liabilities	2,624	2,017
Other non-current financial liabilities	1,466	690
Total non-current liabilities	11,741	12,986
Current liabilities
Loans and borrowings	4,441	2,818
Lease liabilities	840	757
Trade payables	7,455	5,320
Other current liabilities	2,735	3,217
Other current financial liabilities	961	909
Total current liabilities	16,432	13,021
Total liabilities	28,173	26,007
TOTAL EQUITY AND LIABILITIES	$ 75,072	$ 31,856

Consolidated statement of chang

Consolidated statement of changes in equity - USD ($) $ in Thousands	Share Capital & Issuance Premium	Accumulated Deficit	Share-based Compensation	Translation Reserve	Total
Balance at Dec. 31, 2018		$ (143,538)	$ 7,218	$ (1,171)	$ 52,117
Balance (in Shares) at Dec. 31, 2018	189,608
Loss for the year		(43,100)			(43,100)
Other comprehensive income				253
Total comprehensive income for the year		(43,100)		253	(42,847)
Transactions with owners in their capacity as owners:
Issuance of shares					10,040
Issuance of shares (in Shares)	10,040
Deduction of transaction costs					(458)
Deduction of transaction costs (in Shares)	(458)
Share-based compensation costs			872		872
Balance at Dec. 31, 2019		(186,638)	8,090	(918)	19,724
Balance (in Shares) at Dec. 31, 2019	199,190
Loss for the year		(28,662)			(28,662)
Other comprehensive income				(383)	(383)
Total comprehensive income for the year		(28,662)		(383)	(29,045)
Transactions with owners in their capacity as owners:
Issuance of shares					14,186
Issuance of shares (in Shares)	14,186
Deduction of transaction costs					(311)
Deduction of transaction costs (in Shares)	(311)
Share-based compensation costs			1,295		1,295
Balance at Dec. 31, 2020		(215,300)	9,385	(1,301)	5,849
Balance (in Shares) at Dec. 31, 2020	213,065
Loss for the year		(29,002)			(29,002)
Other comprehensive income				264	264
Total comprehensive income for the year		(29,002)		264	(28,738)
Transactions with owners in their capacity as owners:
Issuance of shares					75,339
Issuance of shares (in Shares)	75,339
Deduction of transaction costs					(6,773)
Deduction of transaction costs (in Shares)	(6,773)
Share-based compensation costs			1,222		1,222
Balance at Dec. 31, 2021		$ (244,302)	$ 10,607	$ (1,037)	$ 46,899
Balance (in Shares) at Dec. 31, 2021	281,631

Consolidated statement of cash

Consolidated statement of cash flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Operating loss	$ (26,841)	$ (27,123)	$ (43,169)
Depreciation and amortization	3,036	3,332	3,420
Impairment	0	273	6,292
Share-based compensation	1,222	1,295	872
Other non-cash transactions	(325)	26	1
Cash used in operations before working capital changes	(22,908)	(22,197)	(32,584)
Increase (-) / Decrease (+) in inventories	413	(1,132)	615
Increase (-) / Decrease (+) in receivables	(1,383)	2,851	12,188
Increase (+) in payables	1,330	234	(2,508)
Net cash outflow from operating activities	(22,548)	(20,244)	(22,289)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(896)	(537)	(73)
Interests received	11	0	0
Net cash outflow from investing activities	(885)	(537)	(73)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of shares (net of transaction costs)	68,566	13,875	9,582
Proceeds from the issuance of long-term debt	0	2,316	10,111
Payment of long-term debt	0	0	(589)
Payment of lease liability	(1,057)	(831)	(815)
Payment of interest	(1,011)	(1,070)	(324)
Net cash inflow from financing activities	66,498	14,290	17,965
Net increase (+) / Decrease (-) in cash and cash equivalents	43,065	(6,491)	(4,397)
Cash and cash equivalents at beginning of the financial year	15,953	22,050	26,203
Effect on exchange rate changes	(520)	394	244
Cash and cash equivalents at end of the financial year	$ 58,498	$ 15,953	$ 22,050

Status and Principal Activity

Status and Principal Activity	12 Months Ended
	Dec. 31, 2021
Status and principal activity [Abstract]
Status and principal activity	NOTE 1: Status and principal activity When used in this report, all references to “MDxHealth”, the “company”, “we”, “our” and “us” refer to MDxHealth, SA and its subsidiaries. MDxHealth is a limited liability company domiciled in Belgium, with offices and labs in Belgium, the United States and The Netherlands. MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Applying its DNA methylation platform and proprietary biomarkers, the Company helps address a large and growing unmet medical need for better cancer diagnosis and treatment information. The Company develops and commercializes advanced molecular diagnostic products for personalized cancer treatment that provide physicians with tools to aid in the diagnosis and or prognosis of cancers, and aid in the physician’s ability to predict disease progression and response to therapy. MDxHealth’s products and pipeline cover primarily urologic cancers, but in addition, MDxHealth has numerous proprietary biomarkers for other solid cancer types ready for development. MDxHealth offers its laboratory solutions from our state-of-the-art, 13,448 sqft, College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified, molecular laboratory facility located at its U.S. headquarters in Irvine, California. MDxHealth also operates a molecular laboratory facility, MDxHealth B.V., located in Nijmegen, the Netherlands. This site is ISO 13485:2016 certified and operates a management quality system with the following scope: The design and development, manufacture, service laboratory activities and client services of in vitro diagnostic test kits, in vitro diagnostic reagents used for molecular diagnostic detection of oncological diseases. The Company is headquartered in Belgium. The parent company, MDxHealth SA, has its registered and corporate office in Cap Business Center, Rue d’Abhooz 31, 4040 Herstal, Belgium. MDxHealth, Inc., the Company’s U.S. subsidiary, is located at 15279 Alton Parkway, Suite 100, Irvine, CA 92618, United States. MDxHealth B.V., the Company’s Dutch subsidiary, is located at Transistorweg 5, 6534 Nijmegen, The Netherlands. The functional and presentation currency is the US Dollar.

Summary of Significant Accounti

Summary of Significant Accounting policies	12 Months Ended
	Dec. 31, 2021
Disclosure of significant accounting policies [text block] [Abstract]
Summary of Significant Accounting policies	NOTE 2: Summary of Significant Accounting policies 2.1. Basis of preparation and statement of compliance MDxHealth’s consolidated financial statements of have been prepared in accordance with the International Financial Reporting Standards (IFRS) and interpretations issued by the IFRS Interpretation Committee (IFRS-IC) applicable to companies reported under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board (IASB) and as adopted by the EU (“EU-IFRS”), collectively “IFRS”. The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. All amounts are presented in thousands of US Dollars ($) unless otherwise indicated, rounded to the nearest thousand. 2.2. Basis of consolidation The consolidated financial statements incorporate the financial statements of MDxHealth SA (Belgium) and its wholly-owned subsidiaries, including MDxHealth Inc. (United States), and MDxHealth BV (The Netherlands) for each fiscal year ending on December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. The acquisition method of accounting is used to account for business combinations by the Company. All intercompany balances, profits and transactions are eliminated upon consolidation. 2.3. Going Concern The Company has experienced net losses and significant cash used in operating activities since its inception in 2003, and as of December 31, 2021, had an accumulated deficit of $244.3 million, a net loss of $29.0 million, and net cash used in operating activities of $22.5 million. Management expects the Company to continue to incur net losses and have significant cash outflows for at least the next twelve months. While these conditions, among others, could raise doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure. As of December 31, 2021, the Company had cash and cash equivalents of $58.5 million. Taking into account the above financial situation and on the basis of the most recent business plan, the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This assessment is based on forecasts and projections within management’s most recent business plan as well as the Company’s expected ability to realize cost reductions should these forecasts and projections not be met. 2.4. Use of estimates and judgments Management makes certain critical accounting estimates and management judgment when applying the Company’s accounting policies, which affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are continuously evaluated based on historical experience and other factors, including expectations of future events, which are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. The areas where assumptions and estimation uncertainties in the financial statements have potentially the most significant effect in 2021, are listed below: Revenue recognition (see Note 3): The Company analyzes historical collection data on a quarterly basis and makes adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. Deferred income tax (see Note 8) Management estimates unused tax credits and tax losses to the extent that it is probable that taxable profit will be available against which the tax credits and tax losses can be utilized. On December 31, 2021, the Company had a consolidated net tax loss carried forward amounting to $305,022,000 (2020: $276,166,000; 2019: $279,752,000), implying a potential deferred tax asset of $76,255,500 (2020: $69,041,000; 2019: $82,751,000). No deferred tax assets have been recognized on December 31, 2021, 2020 and 2019. Impairment Testing (see Note 9 and 10) Management periodically assesses whether there are events or circumstances that indicate that the carrying amount of the intangible or tangible asset may not be recoverable. When such indications exist, management estimates the recoverable amount and records an impairment accordingly. Management estimates indications exist that intangible assets ConfirmMDx and SelectMDx could be impaired and has accordingly performed an impairment test which is described in Note 9. Key underlying estimates are considered to be cashflows and the weighted average cost of capital. In addition, as of December 31, 2021, 2020, and 2019, the Company had no outstanding goodwill remaining after the company fully impaired its goodwill in 2019. Share-Based Payments (see Note 22) Management estimates the fair value of the equity-settled share-based payment transactions by using the Black-Scholes option valuation model: ● The dividend return is estimated by reference to the historical dividend payment of the Company. Currently, this is estimated to be zero as no dividends have been paid since inception. ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant. ● Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date Going Concern (note 2.3) Management needs to make significant judgements whether the Company will have sufficient liquidity to continue operations during the next twelve months. We refer to Note 2.3 for management assessment. Financial liabilities (note 14) Other financial liabilities are accounted for at fair value through P&L and include ● the contingent consideration related to the acquisition of NovioGendix in 2015. The fair value of this contingent consideration is reviewed on a regular basis and includes management’s estimates related to the risk-adjusted future cash flows of different scenarios discounted using appropriate interest rates. The structure of the possible scenarios and the probability assigned to each one of them is reassessed by management at every reporting period and requires judgement from management about the outcome and probability of the different scenarios. ● the derivative financial liability for the initial Kreos drawdown fee of €630,000 ($713,538) that initially is based upon the evolution of the share price of MDxHealth and also includes management’s estimates on probabilities that either payment or conversion will be requested by Kreos. 2.5. New Standards, Interpretations and Amendments 2.5.1. New Standards, Interpretations and Amendments adopted by the Company The accounting policies have been consistently applied by the Company and are consistent with those used in previous years. In the current financial year, the Company has applied the amendments to IFRS standards issued by the IASB for the annual period starting on 1 January 2021. This adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements. 2.5.2. Standards and Interpretations issued but not yet effective in the current period Certain new accounting standards and amendments to standards have been published but were not mandatory for 31 December 2021 reporting period. No amendments to standards that are issued but not yet effective are considered to affect the Company’s accounting policies or any of the disclosures when applied for the first time. 2.6. Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The Company’s functional and presentation currency is the U.S. dollar based on the continuing development of the commercial activities in the U.S. market. Foreign currency transactions are translated into the functional currency using the exchange rates at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. The results and financial positions of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that balance sheet ● Income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates, and ● All resulting exchange differences are recognized in other comprehensive income. 2.7. Revenue recognition Performance obligations and timing of revenue recognition The majority of the Company’s revenue is derived from laboratory services with revenue recognized at a point in time when control of the services has transferred to the customer. This is generally when the test results are delivered to the customer. Minor other Company’s revenue is derived from license fees and royalties: ● License fees are recognized when the Company has fulfilled all conditions and obligations. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. ● Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. License up-front (signature fees) and non-refundable fees for access to prior research results and databases are recognized when earned, if the Company has no continuing performance obligations and all conditions and obligations are fulfilled. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. Royalties are generated from the sales by third parties of products or services which incorporate the Company’s proprietary technology. Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. Determining the transaction price A large portion of the Company’s revenues are derived from Medicare, which has set a fixed price (via a Local Coverage Determination or “LCD”) for the Company’s ConfirmMDx test. Therefore, the amount of revenue recognized from Medicare for ConfirmMDx is determined by reference to the fixed price in the LCD. For other commercial insurance companies for ConfirmMDx, SelectMDx, and Urinary Tract Infection (UTI) where there is no certainty of the amount that will be paid for services rendered, the Company uses historical collection data – on an individual payor basis – to estimate its future collection and corresponding revenues that should be recognized for each type of test. The Company analyzes historical collection data on a monthly basis and makes monthly adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. When historical collection data is insufficient to estimate future collections, the Company defaults to cash basis, meaning that revenues will not be recognized until actual cash payment is received from the payor. Total revenue in any given year includes amounts related to tests performed in previous years as: ● unrecognized amounts are collected; ● recognized amounts are collected for different amounts than initially accrued for; and ● balances outstanding for more than 12 months are reversed. 2.8. Segment information Information for the Company’s operating segments has been determined by reference to the information used by the chief operating decision maker (“CODM”) of the Company to review the performance of the Company and in making decisions on allocation of resources, the nature of the activities and the management structure and accountabilities. The Company’s CEO has been identified as the chief operating decision maker in accordance with his designated responsibility for the allocation of resources to operating segments and assessing their performance through periodic reporting. The CODM periodically reviews the Company’s performance based on information at a company level. The Company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing, or the out-licensing of the Company’s patented DNA methylation platform and biomarkers. On an ancillary and opportunistic basis, the Company may engage in contracting out its R&D and scientific expertise to commercial and non-commercial entities. The Company is not organized, nor does it operate along business lines and all functions supported all the Company’s commercial endeavors. 2.9. Externally acquired intangible assets Intangible assets are recognized on business combinations if they are separable from the acquired entity or give rise to other contractual/legal rights. The amounts ascribed to such intangibles are determined using appropriate valuation techniques. Externally generated intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Externally acquired patents and software licenses are initially recognized at cost and are subsequently amortized on a straight-line basis over their estimated useful lives on the following basis: ● Patents: shorter of 5 years or the remaining patent life ● Software: shorter of 5 years or the software license period ● Developed technology: 10 years ● In-Process Research and Development: indefinite until the completion or abandonment of the associated research and development effort. 2.10. Internally generated intangible assets (development costs) Development costs are capitalized if it can be demonstrated that: ● It is technically feasible to develop the product for it to be sold; ● Adequate resources are available to complete the development; ● There is an intention to complete and sell the product; ● The Company is able to sell the product; ● Sale of the product will generate future economic benefits; and, ● Expenditures on the project can be measured reliably. Internally generated intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Amortization over the asset’s useful life shall begin when the asset is available for use. 2.11. Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Repair and maintenance costs are charged to the income statement as incurred. Gains and losses on the disposal of property, plant and equipment are included in other income or expenses. Depreciation is charged to write off the cost or valuation of assets over their useful lives, using the straight-line method, on the following basis: ● Equipment: 5 years ● IT hardware and software: 3 years ● Furniture: 5 years ● Vehicles: 5 years ● Leasehold improvements: in line with the lease agreement period 2.12. Right-of-use assets and liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life (see 2.11) and the lease term. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets: The Company applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered of low value (i.e., below $5,000). Lease payments on short-term leases and low-value assets are recognized in the consolidated statement of profit or loss as incurred. 2.13. Impairment of assets Intangible assets that have an indefinite useful life are not subject to amortizations and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. 2.14. Inventories Inventories are initially recognized at cost, and subsequently at the lower of cost and net realizable value. Cost comprises merely purchase costs, as the inventory consists solely of raw materials. Raw materials are not ordinarily interchangeable, and they are as such accounted for using the specific identification of their individual cost. The Company does not account for work in progress and finished products. 2.15. Government Grants A government grant is only recorded as a receivable when (i) the grant has been approved by the granting party, (ii) the amounts are measurable, and (iii) the Company believes it will meet the conditions necessary to be able to receive/use the grant. Government grants are recognized as other operating income over the life of the grant as the required or planned activities are performed and the related costs are incurred, and when there is reasonable assurance that the Company will comply with the conditions of the grant. 2.16. Cash and cash equivalents Cash and cash equivalents are carried on the balance sheet at nominal value. For the purposes of the cash flow statements, cash and cash equivalents comprise cash on hand, deposits held on call with banks, other short-term highly liquid investments and bank overdrafts. Bank overdrafts, if any, are included in borrowings included in current liabilities. 2.17. Taxation Current tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Deferred income tax is provided in full using the “balance sheet liability method”, on temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognized for all taxable differences. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority. 2.18. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. 2.19. Financial Assets The financial assets consist mainly of trade receivables and other current assets (deposits). Classification and measurement on initial recognition The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price. Trade receivables do not carry any interest and are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses, where applicable. Subsequent measurement After initial recognition, trade receivables and some other current assets are measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses. 2.20. Financial Liabilities The financial liabilities consist mainly of loans and borrowings, lease liabilities, trade and other payables and other financial liabilities that include derivative financial liabilities and contingent consideration related to business combinations. 2.20.1. Measurement on initial recognition At initial recognition financial liabilities are measured at fair value minus transaction costs unless the financial liability is carried at fair value through profit or loss, in which case the transaction costs are immediately recognized in profit or loss. The best estimate of the fair value at initial recognition is usually the transaction price, represented by the fair value of the consideration given or received in exchange for the financial instrument. Any difference between the fair value estimated by the entity and the transaction price (“day one gain or loss”) is recognized: ● in the income statement if the estimate is evidenced by a quoted price in an active market; and ● deferred as an adjustment to the carrying amount of the financial instrument in all other cases. The fair value of the contingent consideration payable at the date of acquisition is computed as the sum of the probability weighted values of the fair values of the purchase prices associated with each of the potential product development routes. The fair value of each route is in turn computed as the sum of the survival probability discounted present values of the contingent payments in each such route including the milestone and commercialization payments. Any other financial liability included in the consideration payable for a business combination is recorded at fair value at the date of acquisition. The fair value of the financial derivative financial instrument related to the initial drawdown fee of the loan which is either convertible into shares or repayable at 150% is computed as the sum of the probability weighted values of the fair values associated with each of the possible outcomes further described in note 14. 2.20.2. Subsequent measurement After initial recognition, loans & borrowings, lease liabilities, trade and other payables, are measured at amortized cost using the effective interest method. The contingent consideration and the derivative financial liability of the Kreos-drawdown fee are measured at fair value are reviewed on a regular basis, and at least at each reporting date, and any changes in fair value are recorded in the consolidated statement of profit and loss. 2.21. Retirement benefit schemes and employee savings schemes Payments to defined contribution employee savings schemes are charged as an expense as they fall due. The Company does not offer nor operate any material defined benefit schemes for its employees. With respect to Belgian pension plans and as explained in Note 21, the Company has considered the potential impact of the employer’s legal obligation to guarantee a minimum return on the Belgian pension plans and that this was assessed not to be significant. 2.22. Share-based compensation plans for personnel, directors and business associates The Company grants stock options in accordance with several share-based compensation plans in consideration for services performed by personnel, directors and business associates. The cost of the services rendered is measured at the fair value of the granted options and recognized as an expense in the statement of profit or loss. The corresponding credit is recorded directly into equity. The estimate of the number of options which will ultimately vest is revised at each reporting date. The change in estimate is recorded as an expense with a corresponding correction in equity. The received amount, less directly attributable transaction costs, will be recorded as share capital and share premium when the options are exercised.

Revenue and Cost of Goods & Ser

Revenue and Cost of Goods & Services Sold	12 Months Ended
	Dec. 31, 2021
Disclosure of products and services [text block] [Abstract]
Revenue and Cost of goods & services sold	NOTE 3: Revenue and Cost of goods & services sold Revenue Thousands of $ 2021 2020 2019 Services 21,937 18,064 11,443 Licenses 250 250 250 Royalties and other revenues 52 146 92 Total revenue 22,239 18,460 11,785 Revenues related to services are recognized at a point in time while licenses, royalties and other revenues are generally recognized over time as described in Note 2.7. The Company did not recognize any contract assets or contracts liabilities. Total revenue for 2021 was $22,239,000, an increase of 20% as compared to total revenue of $18,460,000 for 2020. Revenues from sales of ConfirmMDx accounted for 91% and 94% of total revenues in 2021 and 2020, respectively. Total revenue for 2020 was $18,460,000 compared to total revenue of $11,785,000 for 2019. During the fourth quarter of 2019, and based on current and historical collections data available at the time, the Company updated certain assumptions to its estimates, primarily related to management’s decision to reduce the amount of time it carries accounts receivable from 24 months to 12 months, which negatively affected the 2019 revenues by $10,078,000. The table below shows a summary of billable test volume by product over 2021 and 2020. Year ended 31 December Product 2021 2020 2019 % Change % Change ConfirmMDx 15,324 14,945 18,195 3% (18)% SelectMDx 13,615 13,201 21,699 3% (39)% At the end of 2021, the Company had concluded agreements with 119 payors for ConfirmMDx (2020: 107; 2019: 90) and 54 payors for SelectMDx (2020: 42; 2019: 32). In 2018 Medicare established a Final Positive Local Coverage Determination for use of ConfirmMDx for Prostate Cancer. In 2021, Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDx program, has issued a draft foundational Local Coverage Determination (LCD) for Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer. The draft foundational LCD identifies evidence supporting the clinical utility of the SelectMDx® for Prostate Cancer test and, when finalized, would support coverage of the test for qualified Medicare patients throughout the United States. Segment revenue The Company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing, or the out-licensing of the Company’s patented DNA methylation platform and biomarkers. However, the Company does distinguish different geographical operating segments based on revenue since the revenues are generated both in United States of America and Europe. In 2021, the Company earned 98.6% (2020: 97.9%; 2019: 100%) of its revenue from external customers from its clinical laboratory testing services and out-licensing of intellectual property. In 2021, the clinical laboratory testing in the U.S. CLIA laboratory represented 97% of the Company’s revenue (2020: 95%; 2019: 95%), while the out-licensing of intellectual property revenue in Europe represented 1.5% (2020: 3%; 2019: 5%). In 2021, Medicare represented the only payer generating over 38% of the Company’s revenues, for a total of $8,509,733 (2020: $8,805,000; 2019: $9,701,928). The amount of its revenue from external customers broken down by location is shown in the table below: Thousands of $ 2021 2020 2019 United States of America 21,785 17,760 10,878 The Netherlands 195 352 339 Belgium 26 29 32 Spain 110 132 194 Poland 23 16 38 Italy 15 38 43 Rest of EU 72 112 197 Rest of the world 13 21 64 Total segment revenue 22,239 18,460 11,785 At the end of 2021, 38% of the non-current assets were located in the US (2020: 40%; 2019: 52%) and the remaining 62% in Europe (2020: 60%; 2019: 48%). Cost of goods & services sold Thousands of $ 2021 2020 2019 Cost of goods & services sold 11,675 10,416 11,755 Total cost of goods & services sold 11,675 10,416 11,755 The costs of goods & services sold include the costs associated with providing testing services to third parties and include the cost of materials, labor (including salaries, bonuses, and benefits), transportation, collection kits, and allocated overhead costs associated with processing samples. Allocated overhead costs include depreciation of laboratory equipment, facility occupancy and information technology costs. Costs associated with processing samples are expensed when incurred, regardless of the timing of revenue recognition.

Nature of Expenses

Nature of Expenses	12 Months Ended
	Dec. 31, 2021
Disclosure of expenses by nature [text block] [Abstract]
Nature of expenses	NOTE 4: Nature of expenses Research and development expenses Thousands of $ Notes 2021 2020 2019 Personnel costs 5 1,949 1,277 1,143 Depreciation and amortization 9/10 1,360 1,203 1,283 Impairment 9 0 273 5,147 Lab consumables 793 390 480 Patent expenses 577 396 0 External research and development collaborator fees 1,020 874 880 Clinical validation 842 0 0 Other expenses 132 130 64 Total research and development expenses 6,673 4,543 8,997 Research and development expenses consist of costs incurred for the development of our products. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and stock-based compensation), reagents and supplies, clinical studies, outside services, patent expenses, depreciation of laboratory equipment, facility occupancy and information technology costs. Research and development expenses also include costs associated with assay improvements and automation workflow for our current suite of products. The Company expenses its research and development expenses in the period in which they are incurred. A change in presentation for clinical validation expenses has been brought in 2021 to report clinical validation expenses in the amount of $842,000 under Research and Development, previously under Selling and Marketing expenses. During 2020, the Company recorded an impairment loss on some of its intangible assets related to previously acquired IP (note 9) and no development expenses were capitalized over the year. A change in presentation for patent expenses has been brought in 2020 to report patent expenses under Research and Development, previously under General and Administrative expenses. Selling and Marketing expenses Thousands of $ Notes 2021 2020 2019 Personnel costs 5 13,402 12,839 12,125 Depreciation 9/10 796 603 562 Professional fees 523 497 255 Marketing expenses 1,761 1,315 2,664 Travel expenses 340 260 837 Offices & facilities expenses 436 503 439 Clinical validation 0 377 546 Other expenses 486 358 381 Total selling and marketing expenses 17,744 16,752 17,809 The Company’s sales and marketing expenses are expensed as incurred and include costs associated with its sales organization, including its direct clinical sales force and sales management, medical affairs, client services, marketing and managed care, as well as technical lab support and administration. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and stock-based compensation), customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated overhead costs. General and administrative expenses Thousands of $ Notes 2021 2020 2019 Personnel costs 5 9,009 9,209 8,465 Depreciation and amortization 9/10 880 1,526 1,575 Professional fees 2,018 1,522 2,538 Offices & facilities expenses 845 530 537 Royalties to third parties 152 107 174 Patent expenses 0 0 890 Board fees & expenses 314 238 170 Other expenses 931 858 847 Total general and administrative expenses 14,149 13,990 15,196 General and administrative expenses include costs for certain executives, accounting and finance, legal, revenue cycle management, information technology, human resources, and administrative functions. These expenses consist primarily of labor costs (including salaries, bonuses, benefits, and stock-based compensation), professional service fees such as consulting, accounting, legal, general corporate costs, and public-company costs associated with the Company’s European listing, as well as allocated overhead costs (rent, utilities, insurance, etc.)

Personnel Costs

Personnel Costs	12 Months Ended
	Dec. 31, 2021
Personnel costs [Abstract]
Personnel costs	NOTE 5: Personnel costs Thousands of $ 2021 2020 2019 The number of employees at the end of the year was: Management (headcount) 4 4 4 Laboratory staff (headcount) 14 10 12 S&M staff (headcount) 111 109 110 G&A staff (headcount) 62 54 51 Total 191 177 177 Their aggregate remuneration comprised: Wages and salaries 18,150 17,552 16,343 Social security costs 1,257 1,275 1,411 Pension costs 594 567 638 Health insurance expenses 2,324 2,093 1,882 Share-based compensation 1,222 1,295 872 Other costs 813 543 587 Total personnel costs 24,360 23,325 21,733 The personnel numbers in the table reflect year-end numbers.

Other Operating Income (Expense

Other Operating Income (Expense), Net	12 Months Ended
	Dec. 31, 2021
Disclosure of other operating income (expense) [text block] [Abstract]
Other operating income (expense), net	NOTE 6: Other operating income (expense), net Thousands of $ 2021 2020 2019 Grant subsidies – The Netherlands 1 382 0 0 Grant subsidies – USA 659 0 0 Fair value adjustments 176 118 (48 ) Impairment 0 0 (1,145 ) Other operating income 53 0 1 Other operating expenses (109 ) 0 (5 ) Total other operating income (expense), net 1,161 118 (1,197 ) 1) 2020 grant income of $88,000 is classified under “Royalties and other revenues” Other operating income was comprised of grant income in the U.S. and The Netherlands as well as the revaluation of the contingent consideration related to the acquisition of NovioGendix in 2015. The increase of $1.0 million for 2021 as compared to 2020 is primarily related to $659,000 grant income from the U.S. Department of Health and Humas Services as well as a $382,000 grant from the Dutch government NOW grants, both considered support for Covid-19 inefficiencies. Management considers there are no pending conditions left. In 2019, the Company fully impaired its goodwill balance of $1,145,000.

Finance Income _ (Expenses)

Finance Income / (Expenses)	12 Months Ended
	Dec. 31, 2021
Disclosure of finance income [text block] [Abstract]
Finance income / (expenses)	NOTE 7: Finance income / (expenses) Thousands of $ 2021 2020 2019 Interest income 11 4 10 Interest on loans and leases (1,875 ) (1,227 ) (318 ) Fair value adjustments (194 ) (118 ) (104 ) Other financial loss (103 ) (198 ) (94 ) Net financial results (2,161 ) (1,539 ) (506 ) The financial results primarily relate to interest charges for the loan facility with Kreos Capital (as explained in detail in note 14) for a total of $1,566,000 and for the interest charges on the lease liability for $229,000. Finally, the change in the interest part of the contingent consideration related to the acquisition of NovioGendix in 2015 represents a total of $196,000 in 2021, $118,000 in 2020 and $104,000 in 2019. Other financial losses relate to bank costs incurred during the year.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2021
Disclosure of income tax [text block] [Abstract]
Income Tax	NOTE 8: Income Tax No income taxes were payable in view of the losses incurred by the Company. On December 31, 2021 the Company had a consolidated net tax loss carried forward amounting to $305,022,000 (2020: $276,166,000; 2019 : $279,752,000), implying a potential deferred tax asset at the then enacted tax rates of $76,256,000 (respectively $69,041,000 in 2020 and $82,751,000 in 2019). The tax losses related to MDxHealth SA in Belgium are available for carry forward indefinitely and amount $84,932,000. Tax losses related to MDxHealth BV in the Netherlands are available for carry forward to a period of 7 years. The Company has no notional interest deduction to offset future taxable profits in 2021, 2020 and 2019. Tax credits (investment deductions) amounted to $372,000 in 2021, $462,000 in 2020 and $422,000 in 2019. It is uncertain if the Company will have taxable profits in the near future to allow all or part of the deferred tax asset to be utilized and as a result, no deferred tax asset was recognized in 2021, 2020 and 2019. The tax reconciliation and the impact of the unrecognized deferred tax assets is as follows: Thousands of $ Income Statement For the years ended December 31 2021 2020 2019 Loss for the year (29,002 ) (28,662 ) (43,100 ) Income tax expense 0 0 575 Loss before income tax (29,002 ) (28,662 ) (43,675 ) Tax using the MDxHealth’s domestic tax rate (25.00 % in 2021, 2020 and 29.58% in 2019) (7,251 ) (7,166 ) (12,919 ) Effect of unused tax losses not recognized as deferred tax assets (7,251 ) (7,166 ) (12,919 ) The Dutch entity also has tax losses carried forward for a total amount of $13.4 million for which no deferred tax asset has been recognized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. If the Company would recognize a deferred tax asset for the tax loss carryforward at December 31, 2021, the deferred tax assets would amount to $3 million.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about intangible assets [text block] [Abstract]
Intangible assets	NOTE 9: Intangible assets Thousands of $ Intellectual and Internally Externally Externally TOTAL Gross value At January 1, 2020 5,143 9,325 4,500 3,300 22,268 Currency translation adjustments (9 ) (2 ) (11 ) Gross value at December 31, 2020 5,134 9,323 4,500 3,300 22,257 Accumulated amortization and impairment At January 1, 2020 (4,404 ) (5,332 ) (1,963 ) (3,300 ) (14,999 ) Additions (274 ) (1,206 ) (450 ) (1,930 ) Impairment (273 ) (273 ) Currency translation adjustments 2 1 3 Accumulated amortization and impairment at December 31, 2020 (4,676 ) (6,810 ) (2,413 ) (3,300 ) (17,199 ) Net value at December 31, 2020 458 2,513 2,087 0 5,058 Gross value At January 1, 2021 5,134 9,323 4,500 3,300 22,257 Gross value at December 31, 2021 5,134 9,323 4,500 3,300 22,257 Accumulated amortization and impairment At January 1, 2021 (4,676 ) (6,810 ) (2,413 ) (3,300 ) (17,199 ) Additions (234 ) (926 ) (450 ) (1,610 ) Accumulated amortization and impairment at December 31, 2021 (4,910 ) (7,736 ) (2,863 ) (3,300 ) (18,809 ) Net value at December 31, 2021 224 1,587 1,637 0 3,448 Amortization of intangible assets are included in research & development expenses, general & administrative expenses, and in selling and marketing expenses in the statement of profit and loss. The externally acquired intangible asset relates to technology acquired in the business combination with NovioGendix in 2015. The estimated remaining amortization period amounts to 3.6 years in 2021, and 4.6 years in 2020. The internally generated intangible assets relate to the capitalized development expenses for ConfirmMDx and SelectMDx over the past years. The estimated remaining amortization period amounts to 2.2 years in 2021 and 3.2 years in 2020. The Company did not capitalize development expenses during 2021, 2020 and 2019. The In-process R&D resulted from the allocation of the purchase price paid for the acquisition of MDxHealth BV in September 2015 and is related to the development of AssureMDx. Development costs for AssureMDx are included in development assets. Considering the uncertainties about the future commercialization of AssureMDx, during 2019, the Company impaired the entire In-Process R&D for $3,300,000, in addition to the previously capitalized development expenses for $1,847,000. The impairment test is based on the projected discounted cash flows resulting from ConfirmMDx and SelectMDx assays, considering a period of ten years. The main assumptions for impairment testing include a discount rate (based on WACC) of 12.16% and a perpetual growth rate of 3.0%. Other assumptions include the year-on-year growth rate of the revenue, gross margin and the operating costs which has been determined by management based on past experience. It was concluded that the value in use is higher than the carrying value of the cash generating unit of $3.4 million. There are no reasonably possible changes in assumptions that would reduce the value in use below its carrying value of the cash generating unit.

Property, Plant and Equipment a

Property, Plant and Equipment and Right of-Use Assets	12 Months Ended
	Dec. 31, 2021
Disclosure of property, plant and equipment [text block] [Abstract]
Property, plant and equipment and right of-use assets	NOTE 10: Property, plant and equipment and right of-use assets In December 2019, the Company entered into a lease agreement (the “Alton Lease”) for approx. 11,000 square feet of office space in Irvine, California. In April 2020, the company amended the Alton Lease to add approx. 8,000 additional square feet of adjacent office space. The term of the Alton Lease is 6 years and commenced in September 2020. In March 2021, the Company amended the Alton Lease a second time for purposes of renewing its existing 13,000 square foot laboratory space for an additional 5 years with a commencement date of October 2021. Under the terms of the Alton Lease Agreement, the Company has an option to extend the Alton Lease for a period of 5 years. In October of 2021, the company entered into a 35-month sublease agreement (the “Second Lease Agreement”) for 6,000 additional office space adjacent to the laboratory. Under the terms of the Alton Lease and Second Lease Agreement, rental payments escalate through the term of each agreement and the Company is subject to additional charges for common area maintenance and other costs. The new lease agreements from 2021 represent an additional right of use assets of a total value of $1,518,000. Thousands of $ Laboratory Furniture IT Leasehold TOTAL Gross value At January 1, 2020 5,256 270 333 563 6,422 Additions 101 163 178 98 540 Disposals (4 ) (4 ) Exchange rate difference arising 2 1 (3 ) 5 5 Gross value at December 31, 2020 5,359 434 504 666 6,963 Accumulated depreciation At January 1, 2020 (4,398 ) (211 ) (272 ) (474 ) (5,355 ) Additions (467 ) (34 ) (77 ) (53 ) (631 ) Disposals 1 4 5 Exchange rate difference arising (10 ) 1 2 (2 ) (9 ) Accumulated depreciation at December 31, 2020 (4,874 ) (244 ) (343 ) (529 ) (5,990 ) Net value at December 31, 2020 485 190 161 137 973 Gross value At January 1, 2021 5,359 434 504 666 6,963 Additions 255 131 158 675 1,219 Disposals (2 ) (2 ) Exchange rate difference arising (329 ) 4 13 (312 ) Gross value at December 31, 2021 5,285 569 673 1,341 7,868 Accumulated depreciation At January 1, 2021 (4,874 ) (244 ) (343 ) (529 ) (5,990 ) Additions (277 ) (64 ) (103 ) (77 ) (521 ) Disposals 2 2 Exchange rate difference arising 334 (7 ) (15 ) 312 Accumulated depreciation at December 31, 2021 (4,817 ) (315 ) (459 ) (606 ) (6,197 ) Net value at December 31, 2021 468 254 214 735 1,671 The right-of-use assets can be presented as follows: Thousands of $ Buildings Vehicles Materials TOTAL Gross value At January 1, 2020 1,595 138 897 2,630 Additions 2,017 114 2,131 Disposals (34 ) (34 ) Gross value at December 31, 2020 3,612 218 897 4,727 Accumulated depreciation At January 1, 2020 (577 ) (55 ) (613 ) (1,245 ) Additions (600 ) (55 ) (116 ) (771 ) Disposals 23 23 Accumulated amortization at December 31, 2020 (1,177 ) (87 ) (729 ) (1,993 ) Net value at December 31, 2020 2,435 131 168 2,734 Gross value At January 1, 2021 3,612 218 897 4,727 Additions 1,518 1,518 Disposals Gross value at December 31, 2021 5,130 218 897 6,245 Accumulated depreciation At January 1, 2021 (1,177 ) (87 ) (729 ) (1,993 ) Additions (752 ) (42 ) (111 ) (905 ) Accumulated amortization at December 31, 2021 (1,929 ) (129 ) (840 ) (2,898 ) Net value at December 31, 2021 3,201 89 57 3,347 The following amounts related to leases are recognized in profit & loss Thousands of $ 2021 2020 2019 Depreciation expense 905 771 751 Interest expense on lease liabilities 229 93 88

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Disclosure of inventories [text block] [Abstract]
Inventories	NOTE 11: Inventories Thousands of $ 2021 2020 Raw materials and consumables 1,911 2,324 Total Inventories 1,911 2,324 Inventories are recognized at the lower of cost or net realizable value. Inventories recognized as an expense during the year ended December 31, 2021 amounted to $3,216,000 (2020: $ 2,959,000; 2019: $ 3,843,000). These were included in cost of sales and services.

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Trade and other receivables	NOTE 12: Trade and other receivables Trade receivables Thousands of $ 2021 2020 Trade receivables 4,582 3,771 Total trade receivables 4,582 3,771 Trade receivables mainly consist of claims due from insurance companies covering the Company’s customers. In 2021, the trade accounts receivable balances were mainly composed of services for ConfirmMDx for Prostate Cancer for $3,805,000 in comparison with $3,438,000 in 2020 while SelectMDx for Prostate Cancer represents a total of $593,000 in 2021 (2020: $316,000). The average Days Sales Outstanding (DSO) stood at 49 days in 2021 compared to 55 days in 2020. In consideration with the revenue recognition methodology further described under note 2.7 of the financials, our total accounts receivable balance could be presented in relation with the claim date of each case sold. A/R by claim date Months Thousands of $ 1-3 months 4-6 months 7-12 months Not due Total ConfirmMDx 1,570 716 1,034 3,320 SelectMDx 80 62 115 59 316 Other 114 2 2 17 135 Total Trade Receivables 1,764 780 1,151 76 3,771 A/R by claim date Months Thousands of $ 1-3 months 4-6 months 7-12 months Not due Total ConfirmMDx 1,644 746 1,256 3,646 SelectMDx 151 203 206 33 593 Other 321 22 343 Total Trade Receivables 2,116 949 1,462 55 4,582 Prepaid expenses and other current assets Thousands of $ 2021 2020 Prepayments 1,022 868 Deposits 89 52 Recoverable VAT 246 123 Grants to be received 235 0 Other 23 0 Total prepaid expenses and other current assets 1,615 1,043 Prepaid expenses mainly consist in prepaid insurance premiums, prepaid maintenance contracts. All financial assets carried at amortized cost are shown net of expected credit losses.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2021
Disclosure of restricted cash and cash equivalents [text block] [Abstract]
Cash and cash equivalents	NOTE 13: Cash and cash equivalents Thousands of $ 2021 2020 Cash and cash equivalents 58,498 15,953 Total cash and cash equivalents 58,498 15,953 The bank balances and cash held by the Company and short-term bank deposits have an original maturity of less than 3 months. The carrying amount of these assets approximates their fair value. The Company had no restricted cash in 2021 and 2020.

Loans, Borrowings, Leases oblig

Loans, Borrowings, Leases obligations and other financial liabilities	12 Months Ended
	Dec. 31, 2021
Loans Borrowings And Lease Liabilities [Abstract]
Loans, Borrowings, Leases obligations and other financial liabilities	NOTE 14: Loans, Borrowings, Leases obligations and other financial liabilities Loans, Borrowings & Lease liabilities Thousands of $ 2021 2020 Non-current loans and borrowings Loans (*) 7,490 10,279 Convertible loans 161 0 Lease liabilities (**) 2,624 2,017 Total non-current loans and borrowings 10,275 12,296 Thousands of $ 2021 2020 Current loans and borrowings Loans 4,170 2,818 Convertible loans 271 0 Lease liabilities 840 757 Total current loans and borrowings 5,281 3,575 (*) The ending balance of $10.3 million as of December 31, 2020, includes the fair value of the derivative financial liability of the initial drawdown fee for an amount of $713,000 which has been presented separately a long-term derivative financial liability which is discussed below. (**) the evolution in the right of use assets is further disclosed in note 10. During 2019, the Company entered into a loan facility with Kreos Capital in the amount of €9.0 million, or approximately $10.2 million. The loan had a term of four years with the first 12 months of interest-only payments followed by 36 months of principal and interest payments. On October 20, 2020, MDxHealth and Kreos Capital executed an amendment to the 2019 loan facility, extending the interest-only period from 12 months to 18 months. As a result of this amendment, repayment of principal has been extended by 6 months, from November 2020 to May 2021. As part of the amendment, the Company agreed to increase the end-of-loan fee by €67,500 (approx. $80,000) as well as to provide for €180,000 of the €9 million loan to be convertible into shares of MDxHealth at a 25% premium to the 30-day volume weighted average price immediately prior to signing the amendment. If exercised, this amount will be reduced from the principal amount due under the loan agreement. In April 2021, MDxHealth and Kreos Capital executed a second amendment to the loan facility, extending the interest-only period from 18 months to 27 months. As a result of this amendment, repayment of principal has been extended from May 2021 to February 2022. As part of the amendment, the Company agreed to increase the end-of-loan fee by an additional €67,500 (approx. $80,000) as well as to provide for an additional €202,500 of the €9 million loan to be convertible into shares of MDxHealth at a 25% premium to the 30-day volume weighted average price 10 days prior to signing the amendment. The convertible part of the loan, representing the first discretionary convertible loan of €180,000 ($203,868) and the second discretionary convertible loan of €202,500 ($229,352) are recognized at their amortized cost under Convertible loan. If exercised, this amount will be reduced from the principal amount due under the loan agreement. In addition, the second amendment provided for a further six-month extension of the interest-only period in the event that the Company would receive gross proceeds for a minimum amount of $30 million in new equity financing. Following the completion of our Initial Public Offering of ADSs in the United States on November 8, 2021, whereby the Company received gross proceeds of $45 million in new equity financing, Kreos granted a six-month extension of the interest-only period through July 2022. Beginning August 2022, until maturity in October 2023, we are required to make monthly interest and principal payments. In addition, as the loan facility is contracted in Euro, the foreign exchange rate impacts the carrying amount. The amortized cost is calculated using the effective interest method, which allocates interests and expenses at a constant rate over the term of the instrument; the effective interest rate for the loan is 19.56%. On April 20, 2020, the Company, through its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2,316,000 as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan has a term of five years and carries an interest rate of 1.0% per year. Payments on the loan are deferred for the first eighteen months following disbursement of the loan, with principal and interest payments beginning on the nineteenth month. Interest on the loan continues to accrue during the eighteen-month deferment period. Cash proceeds from the loan were received in July 2020. In addition to the contracted loans, the Company has several lease obligations. The leases have terms of 3 to 5 years. Maturity of loans and borrowings are as follows at the balance sheet date: Thousands of $ 2021 2020 Loans (including convertible loan) Within one year 4,780 3,644 Years two to five 9,283 11,736 Leases Within one year 1,127 1,040 Years two to five 3,094 2,414 Note: all figures shown in this table are undiscounted and reflect future cash payments (capital and interests) Other financial liabilities Other financial liabilities include the contingent consideration related to the acquisition of NovioGendix in 2015 which is valued at fair value through P&L. The fair value of this contingent consideration is reviewed on a regular basis. The fair value is based on a risk-adjusted future cash flows of different scenarios discounted using appropriate interest rate. The structure of the possible scenarios and the probability assigned to each one of them is reassessed by management at every reporting period and requires judgement from management about the outcome and probability of the different scenarios (see Note 24 for details). It also includes the derivative financial liability of the convertible initial drawdown fee payable to Kreos as follows: ● a drawdown fee of €630,000 ($713,538) is due to Kreos Capital which was not payable in cash but remained outstanding as a “convertible loan” (the “Initial Convertible Loan”). ● Upon the Expiration Date, the convertible loan will convert automatically into ordinary shares at €0.85 per share. ● In lieu of converting the Initial Convertible Loan, Kreos Capital may instead cancel the convertible loan at any time (but before the Expiration Date) after the earlier to occur of (i) a repayment or prepayment in full of the loan, and (ii) sale of the entire issued share capital of MDxHealth. In such case, Kreos Capital will be paid an amount equal to 150% of the principal amount of the Initial Convertible Loan. The fair value of the financial derivative financial instrument related to the initial drawdown fee of the Kreos loan which is either convertible into shares or repayable at 150%, is computed as the sum of the probability weighted values of the fair values associated with each of the possible outcomes. Thousands of $ 2021 2020 Other financial liabilities Other non-current financial liabilities 1 1,466 690 Other current financial liabilities 961 909 Total other financial liabilities 2,427 1,599 A reconciliation of cash and non-cash movements of loans and borrowings, lease liabilities and other financial liabilities is presented below: Thousands of Loans and Borrowings Other financial liabilities For the years ended December 31 2021 2020 2021 2020 Beginning balance 13,097 9,617 1,599 1,599 Cash movements Loans and borrowings repaid 2 (39 ) Loans and borrowings received 2,316 Non-cash movements Reclassification 3 (773 ) 773 Effective interest rate adjustment 536 258 194 118 Foreign exchange rate impact / other (768 ) 941 (59 ) Fair value changes through profit and loss 4 (80 ) (118 ) Ending balance 12,092 13,097 2,427 1,599 1) Included in 2021 the fair value of the derivative financial liability of the initial drawdown fee of $810,000 which was presented separately 2) The amount includes interest paid on loans and borrowings 3) Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately The total change in fair value in 2021 amounts to ($80,000) and is composed as follows: ● ($176,000) for the NovioGendix contingent liability; and, ● $96,000 for the Kreos Derivative Instrument Thousands of $ Lease liabilities For the years ended December 31 2021 2020 Opening balance 2,774 1,385 Cash movements Repayment of lease liabilities (1,057 ) (831 ) Non-cash movements Interest accretion 229 89 New leases 1,518 2,131 Closing balance 3,464 2,774

Contractual Obligations

Contractual Obligations	12 Months Ended
	Dec. 31, 2021
Contractual Obligations [Abstract]
Contractual obligations	NOTE 15: Contractual obligations Thousands of $ 2021 2020 Outstanding commitments for future minimum rent payments, which fall due as follows: Less than one year 215 113 Years 2-5 39 112 Total contractual obligations 254 225 For 2021 and 2020, we refer to note 10 and 14 for the lease liabilities subsequent adoption and application of IFRS 16. Outstanding commitments for future minimum rent payments include rental fees related to leased facilities, and equipment for assets with a value below $5,000 or with short-term duration. These lease contracts can be terminated early with certain indemnity fees. All figures shown assume that the lease contracts will not be terminated early.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other payables [text block] [Abstract]
Trade and other payables	NOTE 16: Trade and other payables Trade accounts payable Thousands of $ 2021 2020 Trade accounts payable 3,192 2,903 Accruals for invoices to be received 4,263 2,417 Total trade accounts payable 7,455 5,320 Other current liabilities Thousands of $ 2021 2020 Payroll 2,703 2,539 Other accruals 32 678 Total other current liabilities 2,735 3,217 In April 2020, the Company also received funding from the U.S. department of Health & Human Services (HHS) of $659,000. At December 31, 2020, as part of the requirements of IAS 20, the Company was still assessing its ability to comply with the terms and conditions related to the HHS grant and was unable to recognize the grant in the income statement. During 2021, the Company recognized the grant in the income statement under other operating income (refer to Note 6 for further details).

Financial Instruments and Fair

Financial Instruments and Fair Value	12 Months Ended
	Dec. 31, 2021
Disclosure of financial instruments designated at fair value through profit or loss [text block] [Abstract]
Financial instruments and fair value	NOTE 17: Financial instruments and fair value The table shows the Company’s significant financial assets and liabilities. All financial assets and liabilities are carried at amortized cost with the exception of the contingent considerations in relation to acquisitions reported at fair value through profit and loss. All financial assets and liabilities are considered to have carrying amounts that do not materially differ from their fair value. Thousands of $ 2021 2020 Fair value Assets At amortized cost Trade receivables 4,582 3,771 Cash and cash equivalents 58,498 15,953 Total financial assets 63,080 19,724 Liabilities At fair value: Other financial liabilities 1,617 1,599 Level 3 Derivative financial liability for Kreos drawdown fee 810 Level 3 Subtotal financial liabilities at fair value 2,427 1,599 At amortized cost: Loans and borrowings 12,092 13,097 Level 2 Lease liabilities 3,464 2,774 Trade payables 7,455 5,320 Subtotal financial liabilities at amortized cost 23,011 21,191 Total financial liabilities 25,438 22,790 Recognized fair value measurements – valuation technique and principal inputs The fair value of the financial instruments has been determined on the basis of the following methods and assumptions: ● The carrying value of the cash and cash equivalents, the trade receivables, other current assets and the trade payables approximate their fair value due to their short-term character; ● The fair value of loans and borrowings applying the Effective Interest Rate (EIR)-method approximates their carrying value (level 2). ○ Applying a market rate would not result in a materially different fair value for the Paycheck Protection Program (PPP) loan with the U.S. Small Business Administration which carries an interest rate of 1% and was obtained as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. ○ Although Kreos-loan was obtained end of 2019 with a nominal fixed interest rate of 9,5 ■ Additional contractually agreed advance and post payments agreed upon with Kreos that have been integrated in the Effective Interest Rate method; ■ During 2020 and 2021, parties negotiated modification to the original agreement resulting in additional consecutive interest-only periods. As compensation for these modifications part of the loan amounts became convertible as described in Note 14, however parties agreed to maintain nominal fixed interest rate in line with the initial agreement.” ● Leases are measured at the present value of the remaining lease payments, using a discount rate based on the incremental borrowing rate at the commencement date of these leases. Their fair value approximates their carrying value. ● The fair value of contingent consideration payable (presented in the year-end statement of financial position under “other non-current financial liabilities” and “other current financial liabilities”) is based on an estimated outcome of the conditional purchase price/contingent payments arising from contractual obligations (level 3). This is initially recognized as part of the purchase price and subsequently fair valued with changes recorded through other operating income in the statement of profit or loss. The Company used a discount rate of 12.16%. The effect of the fair value measurement is $176,000 in the condensed consolidated financial statements. ● The fair value of the derivative financial liability for the initial Kreos drawdown fee of €630,000 ($713,538) initially is based upon the evolution of the share price of MDxHealth as well as the estimated probabilities that either payment or conversion will be requested by Kreos. Whereas share price of MDxHealth can be considered as a level 1 input, the other variables should be considered as level 3 inputs. ● Financial instruments are evaluated based on the mark-to-market report and the unrealized gains (loss) are recognized through the statement of profit or loss. Fair value hierarchy: The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: ● Level 1 ● Level 2 ● Level 3 No financial assets or financial liabilities have been reclassified between the valuation categories during the year. A reconciliation of cash and non-cash movements of level 3 financial liabilities is presented below: Thousands of $ Financial Derivative Instrument Contingent Liability For the years ended December 31 2021 2020 2021 2020 Beginning balance 0 0 1,599 1,599 Cash movements Loans and borrowings repaid Loans and borrowings received Non-cash movements Reclassification (1) 773 Effective interest rate adjustment 194 118 Foreign exchange rate impact / other movements (59 ) Fair value changes through profit and loss 96 (176 ) (118 ) Ending balance 810 0 1,617 1,599 1) Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2021
Disclosure of earnings per share [text block] [Abstract]
Loss per share	NOTE 18: Loss per share The basic loss per share is calculated by dividing the net result attributable to shareholders by the weighted average number of shares outstanding during the year. Years ended December 31 2021 2020 2019 Loss for the year, in thousands of $ (29,002 ) (28,662 ) (43,100 ) Basic and diluted loss per share, in $ (0.24 ) (0.34 ) (0.69 ) Weighted average number of shares 2021 2020 2019 Weighted average number of shares for basic and diluted loss per share 121,935,741 83,199,215 62,579,345 At December 31, 2021, 2020 and 2019, the Company had potential dilutive shares in the form of warrants. Diluted loss per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

Financial Risk Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2021
Disclosure of financial risk management [text block] [Abstract]
Financial Risk Management	NOTE 19: Financial Risk Management Capital management Capital is comprised of equity attributable to shareholders, borrowings, and cash and cash equivalents. The Company aims to maintain a strong capital base in order to maintain investor and creditor confidence and to sustain the future development of the business. The Company’s objectives when managing capital are to maintain sufficient liquidity to meet its working capital requirements, fund capital investment and purchases, and safeguard its ability to continue operating as a going concern. The Company monitors capital regularly to ensure that the statutory capital requirements are met and may propose capital increases to the shareholders’ meeting to ensure the necessary capital remains intact. Credit risk Credit risk arises from cash and cash equivalents, short-term bank deposits, as well as credit exposure to collaboration partners. Credit risk refers to the risks that counterparty will default on its contractual obligations resulting in financial loss to the Group. At the end of 2021, 2020, and 2019, the Company operated with more than 1,000 different customers, systematically reducing credit risk compared to prior periods. In the US healthcare system, and particularly within the molecular diagnostic CLIA laboratory industry, where there are rapid technological advances in diagnostic services, companies provide services to healthcare professionals and their patients, while being reimbursed from commercial and governmental insurance systems. Often these services are provided out of network and without supplier contracts. As a result, there is reimbursement risk, separate from credit risk that is characterized by uncertainty in reimbursement value, delays in payment, and ultimately non-payment. This impacts the Company’s revenue recognition and cash collections. In addition to reimbursement risk associated with commercial third-party payors, credit risk may also arise from amounts due directly from patients. In many cases, payors will cover the entire cost of testing. For example, for tests that fall under the Clinical Laboratory Fee Schedule, there is no co-payment, co-insurance or deductible for patients covered under traditional Medicare. However, patients covered by commercial insurance companies may be responsible for a co-payment, co-insurance, and/or deductible depending on the health insurance plan and individual patient benefit. Credit risk exists for those patients who cannot meet their co-payment or deductible portions. Customer’s compliance with agreed credit terms is regularly and closely monitored. Trade accounts receivable amounted to $4,582,000 at December 31, 2021 and no allowance for expected credit loss was recorded. The Company applies the simplified approach to providing for expected credit losses (ECL) prescribed by IFRS 9, which requires the use of the lifetime expected loss provision for all trade receivables. No ECL has been recorded for other financial assets carried at amortized cost as there is no related credit risk. The credit risk on cash and cash equivalents of $58,498,000 is limited given that the counterparties are banks with high credit scores attributed by international rating agencies. Interest risk In the course on 2019, the Company has entered into a 48-months loan agreement for a total amount of €9 million (approximately $10.2 million), and has been amended in October 2020 and in April 2021 (refer to Note 14 for further details). In application to IFRS 9 given the change in estimated cash-flows following the signed amendment, considering that the modification is non-substantial, the Company recognized in profit and loss the amount of the remeasurement. The amortized cost is calculated using the effective interest method, which allocates interests and expenses at a constant rate over the term of the instrument; the effective interest rate for the loan is 19.56%. In addition, on April 20, 2020, the Company, through its U.S. subsidiary, MDxHealth Inc., has entered into a “Paycheck Protection Program” (PPP) loan with the U.S. Small Business Administration (SBA) in the amount of $2,316,000 as part of the U.S Coronavirus Aid, Relief, and Economic Security (CARES) Act. The amortized cost is calculated using the effective interest method, which allocates interests and expenses at a constant rate over the term of the instrument; the effective interest rate for the loan is 1.00%. Considering the fixed interest rate, the Company is not exposed to interest risk, thus did not perform any sensitivity analysis. Currency risk The functional currency changed from the EURO to the US Dollar as of July 1, 2014. Consequently, the currency risk is concentrated on European operations. As of December 31, 2021, cash on hand, held in EURO amounted to €7,195,000. The Company performed a sensitivity analysis of an increase/decrease of exchange rate on operations of 10%. The exposure of operations to the currency risk is limited to the net amount of €7,037,000 (€741,000 revenue and €7,778,000 costs), resulting in a potential gain of €816,000 in case of an increase of the USD/Euro average exchange for 2021 rate by 10%, and a potential loss of €668,000 in case of a decrease of the same exchange rate by 10%. Liquidity risk The Company manages liquidity risk by maintaining adequate reserves and by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. At the date of this document, the Company has two loan agreements with banks and state institutions, and eleven leases (see notes 14 and 16). For the years ended December 31, 2021 Less than between between Total Carrying Non derivatives Trade payables 7,455 7,455 7,455 Loans 4,780 8,200 1,083 14,063 12,092 Lease liabilities 1,127 915 2,179 4,221 3,464 Total 13,362 9,115 3,262 25,739 23,011 Note: Except for carrying amount, all figures shown in this table are undiscounted and reflect future cash payments The Company is also committed to a potential additional cash out of €945,000 ($1,070,307) if Kreos requests payment of the conversion loan (see note 14). For the years ended December 31, 2020 Less than between between Total Carrying Non derivatives Trade payables 5,320 5,320 5,320 Loans (incl. convertible loan) 3,644 5,568 6,168 15,380 13,097 Lease liabilities 1,040 670 1,744 3,454 2,774 Total 10,004 6,238 7,912 24,154 21,191 Other risks The Company subscribes to certain insurance policies to cover matters such as (i) fire, theft, and other damage to its assets, (ii) product and liability insurance and clinical trial insurance, and (iii) D&O insurance. To date, no significant claims have been made under these insurance policies and there is no guarantee that the insurances will cover all damages if they should ever occur. To date, the Company has received several government grants for various R&D projects. Some of these grant amounts can be re-claimed if the Company does not fulfill all the conditions of the grant agreements.

Share Capital and Reserves

Share Capital and Reserves	12 Months Ended
	Dec. 31, 2021
Disclosure of share capital, reserves and other equity interest [text block] [Abstract]
Share capital and reserves	NOTE 20: Share capital and reserves At December 31, 2021, the Company’s share capital was represented by the following number of shares (units). Only one class of shares (common shares) exists, and they have no par value. For the years ended December 31 2021 2020 Common shares 155,969,226 90,691,449 Total outstanding shares 155,969,226 90,691,449 On November 8, 2021, the Company announced that completion of a capital increase by means of an initial public offering in the United States of 3,750,000 American Depositary Shares, or “ADS” (each representing 10 ordinary shares of the Company with no nominal value per share) at an issue price of $12 per ADS, resulting in gross proceeds of $45.0 million. As a result of this capital increase, its share capital has increased from €90,132,067.69 to €118,662,067.69 and the number of issued and outstanding shares has increased from 118,469,226 to 155,969,226 ordinary shares, through the issuance of a total of 37,500,000 new shares. On January 21, 2021, the company announced the successful pricing of its capital increase with the offering of new ordinary shares. The Company raised €25.0 million ($30.4 million) in gross proceeds by means of a private placement of 27,777,777 new shares at an issue price of €0.90 per share through an accelerated bookbuild offering. As a result of the issuance of new shares, the Company’s share capital increased from €68,998,734.95 to €90,132,067.69 and its issued and outstanding shares increased from 90,691,449 to 118,469,226 ordinary shares. On May 15, 2020, the Company announced that MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively “MVM”), completed their equity investment in the Company for an aggregate amount of €12.7 million ($13.7 Million). As a result of the investment, the Company’s share capital was increased from €56,260,102.01 to €68,998,734.95, through the issuance of 20,162,924 new ordinary shares of the Company at an issue price of (rounded) €0.632 per share. Thousands of $/ Thousands of €/ For the years ended December 31 Share Issuance Share Issuance As of January 1, 2020 62,841 136,349 49,754 112,078 May 2020 – Issuance of 20,162,924 shares (*) 13,875 0 12,460 0 As of December 31st, 2020 76,716 136,349 62,214 112,078 January 2021 – Issuance of 27,777,777 shares (*) 23,632 4,693 19,473 3,867 November 2021 – Issuance of 37,500,000 shares (*) 28,106 12,135 24,412 10,536 As of December 31st, 2021 128,454 153,177 106,099 126,481 (*) net of expenses The capital stock and the issuance premium amounted to the following: Thousands of $/ Thousands of €/ For the years ended December 31 2021 2020 2021 2020 Share Capital as per statutory accounts 143,419 84,903 118,662 68,999 Capital increase costs (14,965 ) (8,187 ) (12,564 ) (6,785 ) Share capital under IFRS 128,454 76,716 106,098 62,214 Issuance premium 153,177 136,349 126,481 112,078 Share capital and issuance premium 281,631 213,065 232,579 174,292 The history of the Share Capital can be found in “General Information; Capital and Shares”.

Retirement Benefit Schemes

Retirement Benefit Schemes	12 Months Ended
	Dec. 31, 2021
Retirement Benefit Schemes [Abstract]
Retirement benefit schemes	NOTE 21: Retirement benefit schemes The Company operates defined contribution schemes for all its qualifying employees. The assets of these schemes are held separately from those of the Company in designated funds. A total cost of $594,000 in 2021 (2020: $567,000) represents contributions payable to these schemes by the Company at rates specified in the rules of the plans. The employees of the Company in Belgium are members of a state-managed retirement benefit scheme operated by the government ( i.e. Because the Company must guarantee the statutory minimum return on these plans, not all actuarial and investment risks relating to these plans are transferred to the insurance company or pension fund managing the plans. The Company has considered the potential impact of the employer’s obligation to guarantee a minimum return and that this was assessed not to be significant.

Share-based payments

Share-based payments	12 Months Ended
	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Share-based payments	NOTE 22: Share-based payments This section provides an overview of the outstanding warrants as of December 31, 2021. The warrants were created within the context of stock-based incentive plans for employees, directors and consultants of the Company. The Company has created several pools of warrants under stock option plans for grant to eligible employees, Directors, and consultants. On March 15, 2012 (195,000), June 15, 2012 (700,000), June 23, 2014 (1,500,000), June 19, 2017 (2,500,000), June 21, 2019 (3,000,000) and May 27, 2021 (3,600,000). In aggregate 12,310,800 warrants were issued, subject to warrants being granted to and accepted by the beneficiaries. 16,150 of these warrants never allocated have become null and void, resulting in a remaining and outstanding 12,294,650 warrants, (i) 2,250,052 warrants were terminated or lapsed, (ii) 577,123 warrants were exercised, (iii) 8,917,625 warrants were granted but not yet exercised, and (iv) 566,000 warrants were not yet granted by the Company. For the year 2021, 304,968 warrants (2020: 357,594) were terminated or lapsed, no warrants were exercised, and 795,250 warrants (2020: 859,999) were vested. As a result, as at December 31, 2021, there are 8,917,625 warrants outstanding, entitling their holders to subscribe to 8,917,625 shares of the Company. Number of potential shares from outstanding warrants 2021 2020 As of January 1 5,766,093 4,250,687 Number of warrants cancelled/forfeited during the year (304,968 ) (357,594 ) Number of warrants granted during the year 3,456,500 1,873,000 As of December 31 8,917,625 5,766,093 The warrants are granted to employees (mainly), consultants or directors of the Company and its subsidiaries. Each warrant entitles its holders to subscribe to one new share of the Company at a subscription price determined by the board of directors, within the limits decided upon at the occasion of their issuance. The warrants issued have generally a term of ten years as of issuance. Upon expiration of their term, the warrants become null and void. In general, the warrants vest in cumulative tranches of 25% per year, provided that the beneficiary has provided at least one year of service. However, there are certain exceptions to this rule which are, if applicable, specified in the relevant stock option plans. The 30,000 warrants granted under the May 2011 Stock Option Plan to the CEO became vested immediately on the date of grant (i.e. December 7, 2010). The warrants granted under the May 2012 Stock Option Plan and under the June 23, 2014 Stock Option Plan to directors all vest on the date of the annual meeting that takes place in the calendar year following the calendar year in which they were granted, provided that the mandate of the relevant director has not ended or been terminated. The warrants granted under the May 2012 Stock Option Plan and under the June 23, 2014 Stock Option Plan to beneficiaries who are not directors all vest in instalments of 25% per year, the first tranche of 25% vesting on the first anniversary date of the date of grant and the following tranches vesting on a quarterly basis. The warrants granted under the June 21, 2019 Stock Option Plan and under the May 27, 2021 Stock Option Plan to specific beneficiaries (Directors and Management Team) may adopt a manual vesting procedure under certain conditions or a particular vesting period over 3 years. The table below presents the outstanding warrants and their exercise price at the end of each accounting year covered by the financial statements: Warrants Weighted average Potential shares Weighted average Granted in 2020 1,873,000 0.81 1,873,000 0.81 Outstanding 31 December 2020 5,766,093 1.74 5,766,093 1 74 Granted in 2021 3,456,500 1.37 3,456,500 1.37 Outstanding 31 December 2021 8,917,625 1.53 8,917,625 1.53 Exercisable at 31 December 2021 3,093,499 2.08 3,093,499 2.08 The following table provides an overview of the outstanding potential shares from warrants per personnel category at December 31, 2021 and 2020: Category 2021 2020 Executive Director 2,950,000 1,950,000 Non-Executive Directors 272,000 272,000 Management team (excluding the Executive Director) 2,938,000 1,738,000 Other employees, consultants, and former service providers 2,757,625 1,806,093 Total outstanding at December 31 8,917,625 5,766,093 The share-based compensation expense recognized in the statement of comprehensive income is given below as is the cumulated amount per the consolidated statement of financial position: Thousands of $ 2021 2020 2019 Share-based compensation 1,222 1,295 872 Cumulated Share-based compensation 10,607 9,385 8,090 The Cumulated Share-based compensation amount is part of the Total Shareholders’ Equity on the balance sheet. This amount is presented on the balance sheet for both exercised and non-exercised warrants. The weighted average exercise price of all outstanding warrants (vested and non-vested warrants; assuming 1 warrant = 1 share) is €1.53 or $ conversion 1.73 at December 31, 2021 (€1,74 or $ conversion 2.14 at December 31, 2020; €2.35 or $ conversion 2.64 at December 31, 2019). The weighted average remaining contractual life of all outstanding warrants at the end of 2021 is 7.18 years (2020: 6.70 years; 2019: 6.74 years). The fair value of each warrant is estimated on the date of grant using the Black-Scholes methodology with the following assumptions: Number of warrants granted Expected duration (months) Dates to to Exercise expected Expected Risk-free to to 15-Mar-12 75,000 120,000 € 1.72 - 67.74 % 3.43 % 78.57 60.56 15-Aug-12 12,000 24,000 € 1.52 - 54.50 % 2.57 % 73.54 61.54 14-Sep-12 - 85,000 € 1.65 - 55.58 % 2.59 % 72.56 60.56 01-Dec-12 - 10,000 € 2.19 - 57.13 % 2.19 % 75.98 57.99 01-Jan-13 65,000 107,000 € 2.00 - 57.13 % 2.09 % 80.97 62.92 01-May-13 - 15,000 € 2.13 - 49.75 % 1.93 % 77.03 58.98 31-May-13 12,000 18,000 € 2.05 - 49.62 % 2.22 % 76.04 57.99 12-Mar-14 76,000 177,000 € 3.60 - 47.75 % 2.24 % 72.69 54.67 01-Apr-14 - 12,000 € 4.32 - 48.82 % 2.21 % 72.03 54.02 30-May-14 18,000 18,000 € 4.25 - 48.68 % 1.86 % 70.09 52.08 23-Jun-14 12,000 12,000 € 4.13 - 48.12 % 1.78 % 75.32 63.29 9-Feb-15 60,000 95,000 € 4.49 - 46.75 % 0.62 % 79.73 61.71 29-May-15 20,000 30,000 € 4.91 - 46.52 % 0.81 % 64.14 52.11 1-Oct-15 - 83,000 € 4.20 - 48.99 % 0.90 % 72.03 54.02 1-Dec-15 - 18,000 € 3.89 - 51.18 % 0.85 % 70.03 52.01 1-Feb-16 - 10,000 € 4.13 - 51.18 % 0.85 % 67.99 49.97 4-Feb-16 50,000 134,000 € 3.78 - 52.49 % 0.72 % 67.89 49.87 2-Apr-16 - 52,000 € 3.62 - 53.40 % 0.58 % 65.33 53.33 29-May-16 30,000 40,000 € 4.13 - 51.85 % 0.54 % 64.11 52.11 22-Jan-16 - 20,000 € 3.83 - 52.81 % 0.86 % 68.32 56.32 1-Dec-16 - 22,000 € 4.65 - 54.16 % 0.75 % 57.99 39.98 1-Jan-17 - 19,000 € 4.56 - 53.84 % 0.73 % 56.98 50.96 1-Apr-17 - 18,000 € 5.41 - 51.80 % 0.81 % 54.02 48.00 11-Apr-17 20,000 200,000 € 5.35 - 51.83 % 0.72 % 65.68 47.67 29-Jul-17 - 10,000 € 4.72 - 50.95 % 0.87 % 50.10 44.05 1-Sep-17 - 34,000 € 4.92 - 48.08 % 0.71 % 60.99 42.97 2-Nov-17 - 99,000 € 4.61 - 45.23 % 0.66 % 52.93 40.90 20-Jun-17 30,000 30,000 € 4.97 - 51,57 % 0.59 % 81.40 63.39 01-Apr-18 - 42,000 € 3,77 - 46.08 % 0.76 % 54.02 42.02 01-Jun-18 50,000 30,000 € 4,97 - 46.15 % 0.77 % 52.01 40.01 01-Jun-18 - 8,000 € 3,66 - 44.04 % 0.73 % 48.99 36.99 05-Dec-18 - 20,000 € 1,73 - 57.56 % 0.79 % 45.86 33.86 24-Jan-19 - 191,000 € 1,64 - 67.56 % 0.77 % 62.24 50.20 16-May-19 - 1,508,000 € 1,49 - 75.78 % 0.38 % 58.55 46.52 01-Nov-19 - 8,000 € 1,01 - 82.15 % 0.00 % 64.99 46.98 01-Dec-19 - 12,000 € 1,02 - 81.95 % 0.00 % 64.01 45.99 01-Jan-20 - 6,000 € 1,02 - 81.00 % 0.00 % 62.99 50.99 01-Feb-20 - 2,000 € 0,98 - 80.26 % 0.00 % 61.97 49.67 01-Mar-20 - 4,000 € 0,89 - 80.59 % 0.00 % 61.02 49.02 01-Jun-20 - 6,000 € 0,85 - 86.64 % 0.00 % 57.99 45.99 01-Oct-20 - 2,000 € 0,80 - 85.20 % 0.00 % 53.95 35.97 15-Jul-20 - 225,000 € 0,80 - 85.89 % 0.00 % 56.51 38.53 01-Jul-19 60,000 20,000 € 1,28 - 78.70 % 0.07 % 69.01 51.02 24-Jul-19 - 980,000 € 1,24 - 78.64 % 0.00 % 68.25 50.27 15-Jul-20 - 1,598,000 € 0,80 - 85.89 % 0.00 % 56.52 38.53 30-Jul-20 20,000 - € 1,28 - 87.02 % 0.00 % 56.02 38.04 01-Oct-20 - 10,000 € 1,28 - 85.20 % 0.00 % 53.95 35.97 01-Mar-21 - 2,000 € 1.08 - 65.06 % 0.00 % 48.99 31.00 03-May-21 - 8,000 € 1.16 - 64.59 % 0.01 % 46.92 28.93 01-Jun-21 - 4,000 € 1.18 - 65.82 % 0.01 % 45.96 27.98 27-Jul-21 - 30,000 € 1.36 - 63.36 % 0.00 % 44.12 26.14 27-Jul-21 - 202,500 € 1.36 - 63.36 % 0.00 % 44.12 26.14 24-Nov-21 - 40,000 € 1.05 - 60.78 % 0.14 % 49.25 37.25 03-Jul-21 - 2,570,000 € 1.38 - 63.10 % 0.04 % 44.91 26.93 07-Jul-21 - 600,000 € 1.39 - 63.11 % 0.00 % 44.78 26.79 The above inputs for the Black-Scholes model have been determined based on the following: ● The dividend return is estimated by reference to the historical dividend payment of the Company. Currently, this is estimated to be zero as no dividends have been paid since inception. ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant. ● Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2021
Disclosure of related party [text block] [Abstract]
Related parties	NOTE 23: Related parties Transactions between the Company and its employees, consultants or Directors are described below. There were no other related party transactions. Remuneration of key management personnel During the year ended December 31, 2021, the executive management team included four members: 1. Chief Executive Director, Mr. Michael McGarrity 2. Executive Vice President of Corporate Development & General Counsel, Mr. Joseph Sollee 3. Chief Finance Officer, Mr. Ron Kalfus 4. Chief Commercial Officer, Mr. John Bellano Their combined remuneration package, including employer taxes, amounted to the following: Thousands of $/ except per personnel, warrants & For the years ended December 31 2021 2020 2019 Number of management members and Executive Directors 4 4 4 Short-term employee benefits 1,545 1,535 1,101 Post-employment benefits 52 23 26 Other employment costs 207 174 65 Termination benefits 0 0 1,111 Total benefits 1,804 1,732 2,303 IFRS share-based compensation expense 982 596 34 Number of warrants offered 2,200,000 1,183,000 2,330,000 Cumulative outstanding warrants 5,888,000 3,688,000 2,505,000 Exercisable warrants 1,282,238 1,036,250 160,000 The following table sets forth the number of warrants that were exercised, granted and accepted in aggregate by the four members of the executive management team: 2021 2020 2019 Number of warrants exercised 0 0 0 Number of new warrants granted and accepted 2,200,000 1,183,000 2,330,000 Annualized IFRS cost for existing warrants $ 982,000 $ 596,000 $ 34,000 No loans, quasi-loans or other guarantees are outstanding with members of the executive management team. Remuneration of the Board The total remuneration of the Board of Directors (including the Executive Director) in 2021, 2020 and 2019 was $863,000, $775,000 and $484,000 respectively (excluding VAT, stock-based compensation and reimbursement of expenses). No advances or credits have been granted to any member of the Board of Directors. None of the members of the Board of Directors have received any non-monetary remuneration other than warrants as disclosed above. Transactions with Non-Executive Directors Since 2012, the Non-Independent Directors do not receive a fee payment for attending and preparing for Board meetings or for assisting the Company with Board matters. They receive reimbursement for expenses directly related to the Board meetings, totaling less than $12,000 in 2021. The Independent Directors receive a fee for attending and preparing meetings of the Board of Directors and for assisting the Company with Board matters, and they receive reimbursement for expenses directly related to the Board meetings. In 2021, 2020 and 2019, respectively $302,000, $231,000 and $135,000 were paid as fees and expense reimbursement to independent members of the Board of Directors. A total of 20,000 warrants were granted to Non-Executive Directors in 2021 and no warrants were exercised in 2021.

Significant Agreements, Commitm

Significant Agreements, Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Disclosure of commitments and contingent liabilities [text block] [Abstract]
Significant agreements, commitments and contingencies	NOTE 24: Significant agreements, commitments and contingencies Fair value of Other financial liabilities On September 18, 2015, MDxHealth acquired MDxHealth BV (former NovioGendix), a Dutch molecular diagnostic research and service company with expertise in the urological oncology. The terms of the acquisition consisted of initial consideration paid in 1,086,956 shares of MDxHealth common stock, issued at €4.14 representing the average closing price of the Company’s shares on Euronext Brussels during a period of 30 days ending on September 17, 2015. In addition to this equity, additional cash consideration of €250,000 was paid. On top of the acquisition price, MDxHealth is committed to pay future milestone fees. The Company paid €1,000,000, being $1,105,000 regarding these milestone fees in 2017. The fair value of this contingent consideration as of December 31, 2021 is estimated at $1,617,000 over the period 2021-2022 (2020: $1,599,000; 2019: $1,599,000). The Company is contractually required to pay at maturity to the holder of the obligation the amount of maximum $2,200,000. Collaborative research agreements and clinical research agreements The Company has entered into numerous agreements with universities, medical centers and external researchers for research and development work and for the validation of the Company’s technology and products. These agreements typically have durations of one to three years. The Company must pay fixed fees to the collaborators and in exchange typically receives access and rights to the results of the work. MDxHealth collaborates on research and clinical development with many of the world’s leading academic and government cancer research institutes. These important relationships provide the Company with additional resources and expertise for clinical marker validation as well as access to patient samples for testing. MDxHealth’s collaborators include such prestigious institutions as Johns Hopkins University Medical Institutions (US), Duke University Medical Center (US), Harvard Medical School (US), Cleveland Clinic (US), University of Colorado (US), University of California at Los Angeles (US), Radboud University (The Netherlands) and University of Gent (Belgium) among others. Intellectual property in-licensing agreements The Company has entered into numerous agreements with universities and companies for in-licensing intellectual property. These agreements typically require the Company to pay an up-front fee, annual maintenance fees and/or minimum annual royalty fees, legal fees related to the patents, and certain milestone and royalty fees if the patents are eventually used in a commercialized product. In addition, the Company must provide the licensor with periodic reports. Commercial and intellectual property sub-licensing agreements The Company has entered into numerous partnering and sub-licensing agreements. In regard to the Company’s developed tests, the Company has entered into a range of marketing and sales arrangements with commercial entities. These important relationships provide the Company with additional resources and infrastructure to expand the geographic reach and awareness of the Company’s solutions, primarily in relation to the ConfirmMDx and SelectMDx tests. MDxHealth’s marketing partners include Cerba Healthcare (Belgium), Ferrer Internacional (Spain), Teva Pharmaceuticals (Israel), and SouthGenetics (South and Central America), LifeLabs (Canada) and, in the US, LabCorp, Miraca Life Sciences, Bostwick Laboratories. In regard to intellectual property that MDxHealth has developed or improved, MDxHealth has sublicensed certain of its non-core epigenetic technologies to commercial partners, several of whom have launched products that generate royalties and other fees. These sublicenses include: ● an exclusive sublicense to Laboratory Corporation of America (LabCorp) for the MGMT test (for the North American market only, of indefinite duration, and limited to service testing only). MDxHealth retained certain rights to develop and commercialize the MGMT test as a companion diagnostic on a worldwide basis. LabCorp began to commercialize the MGMT test in North America in 2008. ● non-exclusive sublicense agreements for the Company’s patented methylation specific PCR (MSP) technology for diagnostic applications, in exchange for certain license fees and running royalties, to several partners including oncgnostics GmbH, Qiagen GmbH and Takara Bio. Litigation As of the date of this document and as far as MDxHealth is aware, the Company is not involved in any material legal proceedings.

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2021
Description of accounting policy for subsidiaries [text block] [Abstract]
Subsidiaries	NOTE 25: Subsidiaries The Company has the following two wholly-owned direct subsidiaries: MDxHealth Inc. Address 15279 Alton Parkway – Suite 100 – Irvine, CA 92618 Incorporation Date April 14, 2003 Number of employees 176 at December 31,2021, 163 at December 31, 2020 and 158 at December 31, 2019. MDxHealth B.V. Address Transistorweg 5, 6534 AT Nijmegen, The Netherlands Incorporation Date October 18, 2006 Incorporated into MDxHealth on September 18, 2015 Number of employees 11 at December 31, 2021, 9 at December 31, 2020 and 11 at December 31, 2019.

Principal Audit Fees and Servic

Principal Audit Fees and Services	12 Months Ended
	Dec. 31, 2021
Principal Audit Fees And Services [Abstract]
Principal audit fees and services	NOTE 26: Principal audit fees and services During the past fiscal year, in addition to their usual activity, the statutory auditor performed additional activities on behalf of the Company mainly for the issuance of special reports related to warrant plans, grant report certification, for participation to the audit committees and for participation to special projects. The detail is presented in the table below: in thousands of $ in thousands of € For the years ended December 31 2021 2020 2019 2021 2020 2019 Audit fee for statutory and consolidated financials 182,125 85,000 111,000 155,000 75,000 99,000 Audit related and other services (IPO in the USA) 200,221 10,000 14,000 170,401 8,000 12,000 Total 382,346 95,000 125,000 325,401 83,000 111,000

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of preparation and statement of compliance	Basis of preparation and statement of compliance MDxHealth’s consolidated financial statements of have been prepared in accordance with the International Financial Reporting Standards (IFRS) and interpretations issued by the IFRS Interpretation Committee (IFRS-IC) applicable to companies reported under IFRS. The financial statements comply with IFRS as issued by the International Accounting Standards Board (IASB) and as adopted by the EU (“EU-IFRS”), collectively “IFRS”. The principal accounting policies applied in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. All amounts are presented in thousands of US Dollars ($) unless otherwise indicated, rounded to the nearest thousand.
Basis of consolidation	Basis of consolidation The consolidated financial statements incorporate the financial statements of MDxHealth SA (Belgium) and its wholly-owned subsidiaries, including MDxHealth Inc. (United States), and MDxHealth BV (The Netherlands) for each fiscal year ending on December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. The acquisition method of accounting is used to account for business combinations by the Company. All intercompany balances, profits and transactions are eliminated upon consolidation.
Going Concern	Going Concern The Company has experienced net losses and significant cash used in operating activities since its inception in 2003, and as of December 31, 2021, had an accumulated deficit of $244.3 million, a net loss of $29.0 million, and net cash used in operating activities of $22.5 million. Management expects the Company to continue to incur net losses and have significant cash outflows for at least the next twelve months. While these conditions, among others, could raise doubt about its ability to continue as a going concern, these consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of its assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure. As of December 31, 2021, the Company had cash and cash equivalents of $58.5 million. Taking into account the above financial situation and on the basis of the most recent business plan, the Company believes that it has sufficient cash to be able to continue its operations for at least the next twelve months from the date of issuance of these financial statements, and accordingly has prepared the consolidated financial statements assuming that it will continue as a going concern. This assessment is based on forecasts and projections within management’s most recent business plan as well as the Company’s expected ability to realize cost reductions should these forecasts and projections not be met.
Use of estimates and judgments	Use of estimates and judgments Management makes certain critical accounting estimates and management judgment when applying the Company’s accounting policies, which affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are continuously evaluated based on historical experience and other factors, including expectations of future events, which are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions. The areas where assumptions and estimation uncertainties in the financial statements have potentially the most significant effect in 2021, are listed below: Revenue recognition (see Note 3): The Company analyzes historical collection data on a quarterly basis and makes adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. Deferred income tax (see Note 8) Management estimates unused tax credits and tax losses to the extent that it is probable that taxable profit will be available against which the tax credits and tax losses can be utilized. On December 31, 2021, the Company had a consolidated net tax loss carried forward amounting to $305,022,000 (2020: $276,166,000; 2019: $279,752,000), implying a potential deferred tax asset of $76,255,500 (2020: $69,041,000; 2019: $82,751,000). No deferred tax assets have been recognized on December 31, 2021, 2020 and 2019. Impairment Testing (see Note 9 and 10) Management periodically assesses whether there are events or circumstances that indicate that the carrying amount of the intangible or tangible asset may not be recoverable. When such indications exist, management estimates the recoverable amount and records an impairment accordingly. Management estimates indications exist that intangible assets ConfirmMDx and SelectMDx could be impaired and has accordingly performed an impairment test which is described in Note 9. Key underlying estimates are considered to be cashflows and the weighted average cost of capital. In addition, as of December 31, 2021, 2020, and 2019, the Company had no outstanding goodwill remaining after the company fully impaired its goodwill in 2019. Share-Based Payments (see Note 22) Management estimates the fair value of the equity-settled share-based payment transactions by using the Black-Scholes option valuation model: ● The dividend return is estimated by reference to the historical dividend payment of the Company. Currently, this is estimated to be zero as no dividends have been paid since inception. ● The expected volatility was determined using the average volatility of the stock over the last two years at the date of grant. ● Risk-free interest rate is based on the interest rate applicable for the 10Y Belgian government bond at the grant date Going Concern (note 2.3) Management needs to make significant judgements whether the Company will have sufficient liquidity to continue operations during the next twelve months. We refer to Note 2.3 for management assessment. Financial liabilities (note 14) Other financial liabilities are accounted for at fair value through P&L and include ● the contingent consideration related to the acquisition of NovioGendix in 2015. The fair value of this contingent consideration is reviewed on a regular basis and includes management’s estimates related to the risk-adjusted future cash flows of different scenarios discounted using appropriate interest rates. The structure of the possible scenarios and the probability assigned to each one of them is reassessed by management at every reporting period and requires judgement from management about the outcome and probability of the different scenarios. ● the derivative financial liability for the initial Kreos drawdown fee of €630,000 ($713,538) that initially is based upon the evolution of the share price of MDxHealth and also includes management’s estimates on probabilities that either payment or conversion will be requested by Kreos.
New Standards, Interpretations and Amendments adopted by the Company	New Standards, Interpretations and Amendments 2.5.1. New Standards, Interpretations and Amendments adopted by the Company The accounting policies have been consistently applied by the Company and are consistent with those used in previous years. In the current financial year, the Company has applied the amendments to IFRS standards issued by the IASB for the annual period starting on 1 January 2021. This adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements. 2.5.2. Standards and Interpretations issued but not yet effective in the current period Certain new accounting standards and amendments to standards have been published but were not mandatory for 31 December 2021 reporting period. No amendments to standards that are issued but not yet effective are considered to affect the Company’s accounting policies or any of the disclosures when applied for the first time.
Foreign currency translation	Foreign currency translation Functional and presentation currency Items included in the financial statements of each of the Company’s entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The Company’s functional and presentation currency is the U.S. dollar based on the continuing development of the commercial activities in the U.S. market. Foreign currency transactions are translated into the functional currency using the exchange rates at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. The results and financial positions of foreign operations that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● Assets and liabilities for each statement of financial position presented are translated at the closing rate at the date of that balance sheet ● Income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates, and ● All resulting exchange differences are recognized in other comprehensive income.
Revenue recognition	Revenue recognition Performance obligations and timing of revenue recognition The majority of the Company’s revenue is derived from laboratory services with revenue recognized at a point in time when control of the services has transferred to the customer. This is generally when the test results are delivered to the customer. Minor other Company’s revenue is derived from license fees and royalties: ● License fees are recognized when the Company has fulfilled all conditions and obligations. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. ● Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. License up-front (signature fees) and non-refundable fees for access to prior research results and databases are recognized when earned, if the Company has no continuing performance obligations and all conditions and obligations are fulfilled. If the Company has continuing performance obligations towards the fees, the fee will be recognized on a straight-line basis over the contractual performance period. Royalties are generated from the sales by third parties of products or services which incorporate the Company’s proprietary technology. Royalties are recognized as revenue once the amounts due can be reliably estimated based on the sale of the underlying products and services and when the collection of the royalties can be reasonably assured. Determining the transaction price A large portion of the Company’s revenues are derived from Medicare, which has set a fixed price (via a Local Coverage Determination or “LCD”) for the Company’s ConfirmMDx test. Therefore, the amount of revenue recognized from Medicare for ConfirmMDx is determined by reference to the fixed price in the LCD. For other commercial insurance companies for ConfirmMDx, SelectMDx, and Urinary Tract Infection (UTI) where there is no certainty of the amount that will be paid for services rendered, the Company uses historical collection data – on an individual payor basis – to estimate its future collection and corresponding revenues that should be recognized for each type of test. The Company analyzes historical collection data on a monthly basis and makes monthly adjustments to its estimates. In accordance with IFRS 15, revenue is recognized where such a variable consideration is included in the transaction price only to the extent that it is highly probable that the amount of revenue recognized will not be subject to significant future reversals as a result of subsequent re-estimation. When historical collection data is insufficient to estimate future collections, the Company defaults to cash basis, meaning that revenues will not be recognized until actual cash payment is received from the payor. Total revenue in any given year includes amounts related to tests performed in previous years as: ● unrecognized amounts are collected; ● recognized amounts are collected for different amounts than initially accrued for; and ● balances outstanding for more than 12 months are reversed.
Segment information	Segment information Information for the Company’s operating segments has been determined by reference to the information used by the chief operating decision maker (“CODM”) of the Company to review the performance of the Company and in making decisions on allocation of resources, the nature of the activities and the management structure and accountabilities. The Company’s CEO has been identified as the chief operating decision maker in accordance with his designated responsibility for the allocation of resources to operating segments and assessing their performance through periodic reporting. The CODM periodically reviews the Company’s performance based on information at a company level. The Company does not distinguish different business segments since most revenues are generated from clinical laboratory service testing, or the out-licensing of the Company’s patented DNA methylation platform and biomarkers. On an ancillary and opportunistic basis, the Company may engage in contracting out its R&D and scientific expertise to commercial and non-commercial entities. The Company is not organized, nor does it operate along business lines and all functions supported all the Company’s commercial endeavors.
Goodwill	Externally acquired intangible assets Intangible assets are recognized on business combinations if they are separable from the acquired entity or give rise to other contractual/legal rights. The amounts ascribed to such intangibles are determined using appropriate valuation techniques. Externally generated intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Externally acquired patents and software licenses are initially recognized at cost and are subsequently amortized on a straight-line basis over their estimated useful lives on the following basis: ● Patents: shorter of 5 years or the remaining patent life ● Software: shorter of 5 years or the software license period ● Developed technology: 10 years ● In-Process Research and Development: indefinite until the completion or abandonment of the associated research and development effort.
Internally generated intangible assets	Internally generated intangible assets (development costs) Development costs are capitalized if it can be demonstrated that: ● It is technically feasible to develop the product for it to be sold; ● Adequate resources are available to complete the development; ● There is an intention to complete and sell the product; ● The Company is able to sell the product; ● Sale of the product will generate future economic benefits; and, ● Expenditures on the project can be measured reliably. Internally generated intangible assets are carried at their cost less any accumulated amortization and any accumulated impairment losses. Amortization over the asset’s useful life shall begin when the asset is available for use.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment. Repair and maintenance costs are charged to the income statement as incurred. Gains and losses on the disposal of property, plant and equipment are included in other income or expenses. Depreciation is charged to write off the cost or valuation of assets over their useful lives, using the straight-line method, on the following basis: ● Equipment: 5 years ● IT hardware and software: 3 years ● Furniture: 5 years ● Vehicles: 5 years ● Leasehold improvements: in line with the lease agreement period
Right-of-use assets and liabilities	Right-of-use assets and liabilities Right-of-use assets: The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life (see 2.11) and the lease term. Right-of-use assets are subject to impairment. Lease liabilities: At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs. In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. Short-term leases and leases of low-value assets: The Company applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered of low value (i.e., below $5,000). Lease payments on short-term leases and low-value assets are recognized in the consolidated statement of profit or loss as incurred.
Impairment of assets	Impairment of assets Intangible assets that have an indefinite useful life are not subject to amortizations and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Inventories	Inventories Inventories are initially recognized at cost, and subsequently at the lower of cost and net realizable value. Cost comprises merely purchase costs, as the inventory consists solely of raw materials. Raw materials are not ordinarily interchangeable, and they are as such accounted for using the specific identification of their individual cost. The Company does not account for work in progress and finished products.
Government Grants	Government Grants A government grant is only recorded as a receivable when (i) the grant has been approved by the granting party, (ii) the amounts are measurable, and (iii) the Company believes it will meet the conditions necessary to be able to receive/use the grant.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents are carried on the balance sheet at nominal value. For the purposes of the cash flow statements, cash and cash equivalents comprise cash on hand, deposits held on call with banks, other short-term highly liquid investments and bank overdrafts. Bank overdrafts, if any, are included in borrowings included in current liabilities.
Taxation	Taxation Current tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Deferred income tax is provided in full using the “balance sheet liability method”, on temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognized for all taxable differences. Deferred tax assets are recognized for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.
Share Capital	Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Financial Assets	Financial Assets The financial assets consist mainly of trade receivables and other current assets (deposits). Classification and measurement on initial recognition The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Company’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price. Trade receivables do not carry any interest and are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses, where applicable. Subsequent measurement After initial recognition, trade receivables and some other current assets are measured at amortized cost using the effective interest method, less provision for impairment based on expected credit losses.
Financial Liabilities	Financial Liabilities The financial liabilities consist mainly of loans and borrowings, lease liabilities, trade and other payables and other financial liabilities that include derivative financial liabilities and contingent consideration related to business combinations.
Measurement on initial recognition	Measurement on initial recognition At initial recognition financial liabilities are measured at fair value minus transaction costs unless the financial liability is carried at fair value through profit or loss, in which case the transaction costs are immediately recognized in profit or loss. The best estimate of the fair value at initial recognition is usually the transaction price, represented by the fair value of the consideration given or received in exchange for the financial instrument. Any difference between the fair value estimated by the entity and the transaction price (“day one gain or loss”) is recognized: ● in the income statement if the estimate is evidenced by a quoted price in an active market; and ● deferred as an adjustment to the carrying amount of the financial instrument in all other cases. The fair value of the contingent consideration payable at the date of acquisition is computed as the sum of the probability weighted values of the fair values of the purchase prices associated with each of the potential product development routes. The fair value of each route is in turn computed as the sum of the survival probability discounted present values of the contingent payments in each such route including the milestone and commercialization payments. Any other financial liability included in the consideration payable for a business combination is recorded at fair value at the date of acquisition. The fair value of the financial derivative financial instrument related to the initial drawdown fee of the loan which is either convertible into shares or repayable at 150% is computed as the sum of the probability weighted values of the fair values associated with each of the possible outcomes further described in note 14.
Subsequent measurement	Subsequent measurement After initial recognition, loans & borrowings, lease liabilities, trade and other payables, are measured at amortized cost using the effective interest method. The contingent consideration and the derivative financial liability of the Kreos-drawdown fee are measured at fair value are reviewed on a regular basis, and at least at each reporting date, and any changes in fair value are recorded in the consolidated statement of profit and loss.
Retirement benefit schemes and employee savings schemes	Retirement benefit schemes and employee savings schemesPayments to defined contribution employee savings schemes are charged as an expense as they fall due. The Company does not offer nor operate any material defined benefit schemes for its employees.
Share-based compensation plans for personnel, directors and business associates	Share-based compensation plans for personnel, directors and business associates The Company grants stock options in accordance with several share-based compensation plans in consideration for services performed by personnel, directors and business associates. The cost of the services rendered is measured at the fair value of the granted options and recognized as an expense in the statement of profit or loss. The corresponding credit is recorded directly into equity. The estimate of the number of options which will ultimately vest is revised at each reporting date. The change in estimate is recorded as an expense with a corresponding correction in equity. The received amount, less directly attributable transaction costs, will be recorded as share capital and share premium when the options are exercised.

Revenue and Cost of Goods & S_2

Revenue and Cost of Goods & Services Sold (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of products and services [text block] [Abstract]
Schedule of revenue	Thousands of $ 2021 2020 2019 Services 21,937 18,064 11,443 Licenses 250 250 250 Royalties and other revenues 52 146 92 Total revenue 22,239 18,460 11,785
Schedule of billable test volume by product	Year ended 31 December Product 2021 2020 2019 % Change % Change ConfirmMDx 15,324 14,945 18,195 3% (18)% SelectMDx 13,615 13,201 21,699 3% (39)%
Schedule of revenue from external customers broken down by location	Thousands of $ 2021 2020 2019 United States of America 21,785 17,760 10,878 The Netherlands 195 352 339 Belgium 26 29 32 Spain 110 132 194 Poland 23 16 38 Italy 15 38 43 Rest of EU 72 112 197 Rest of the world 13 21 64 Total segment revenue 22,239 18,460 11,785
Schedule of cost of goods & services sold	Thousands of $ 2021 2020 2019 Cost of goods & services sold 11,675 10,416 11,755 Total cost of goods & services sold 11,675 10,416 11,755

Nature of Expenses (Tables)

Nature of Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of expenses by nature [text block] [Abstract]
Schedule of research and development expenses	Thousands of $ Notes 2021 2020 2019 Personnel costs 5 1,949 1,277 1,143 Depreciation and amortization 9/10 1,360 1,203 1,283 Impairment 9 0 273 5,147 Lab consumables 793 390 480 Patent expenses 577 396 0 External research and development collaborator fees 1,020 874 880 Clinical validation 842 0 0 Other expenses 132 130 64 Total research and development expenses 6,673 4,543 8,997
Schedule of selling and marketing expenses	Thousands of $ Notes 2021 2020 2019 Personnel costs 5 13,402 12,839 12,125 Depreciation 9/10 796 603 562 Professional fees 523 497 255 Marketing expenses 1,761 1,315 2,664 Travel expenses 340 260 837 Offices & facilities expenses 436 503 439 Clinical validation 0 377 546 Other expenses 486 358 381 Total selling and marketing expenses 17,744 16,752 17,809
Schedule of general and administrative expenses	Thousands of $ Notes 2021 2020 2019 Personnel costs 5 9,009 9,209 8,465 Depreciation and amortization 9/10 880 1,526 1,575 Professional fees 2,018 1,522 2,538 Offices & facilities expenses 845 530 537 Royalties to third parties 152 107 174 Patent expenses 0 0 890 Board fees & expenses 314 238 170 Other expenses 931 858 847 Total general and administrative expenses 14,149 13,990 15,196

Personnel Costs (Tables)

Personnel Costs (Tables)	12 Months Ended
	Dec. 31, 2021
Personnel costs [Abstract]
Schedule of personnel costs	Thousands of $ 2021 2020 2019 The number of employees at the end of the year was: Management (headcount) 4 4 4 Laboratory staff (headcount) 14 10 12 S&M staff (headcount) 111 109 110 G&A staff (headcount) 62 54 51 Total 191 177 177 Their aggregate remuneration comprised: Wages and salaries 18,150 17,552 16,343 Social security costs 1,257 1,275 1,411 Pension costs 594 567 638 Health insurance expenses 2,324 2,093 1,882 Share-based compensation 1,222 1,295 872 Other costs 813 543 587 Total personnel costs 24,360 23,325 21,733

Other Operating Income (Expen_2

Other Operating Income (Expense), Net (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of other operating income (expense) [text block] [Abstract]
Schedule of other operating income expenses net	Thousands of $ 2021 2020 2019 Grant subsidies – The Netherlands 1 382 0 0 Grant subsidies – USA 659 0 0 Fair value adjustments 176 118 (48 ) Impairment 0 0 (1,145 ) Other operating income 53 0 1 Other operating expenses (109 ) 0 (5 ) Total other operating income (expense), net 1,161 118 (1,197 )

Finance Income _ (Expenses) (Ta

Finance Income / (Expenses) (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of finance income [text block] [Abstract]
Schedule of finance income expenses	Thousands of $ 2021 2020 2019 Interest income 11 4 10 Interest on loans and leases (1,875 ) (1,227 ) (318 ) Fair value adjustments (194 ) (118 ) (104 ) Other financial loss (103 ) (198 ) (94 ) Net financial results (2,161 ) (1,539 ) (506 )

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of income tax [text block] [Abstract]
Schedule of tax reconciliation and the impact of unrecognized deferred tax assets	Thousands of $ Income Statement For the years ended December 31 2021 2020 2019 Loss for the year (29,002 ) (28,662 ) (43,100 ) Income tax expense 0 0 575 Loss before income tax (29,002 ) (28,662 ) (43,675 ) Tax using the MDxHealth’s domestic tax rate (25.00 % in 2021, 2020 and 29.58% in 2019) (7,251 ) (7,166 ) (12,919 ) Effect of unused tax losses not recognized as deferred tax assets (7,251 ) (7,166 ) (12,919 )

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about intangible assets [text block] [Abstract]
Schedule of selling and marketing expenses in the statement of profit or loss	Thousands of $ Intellectual and Internally Externally Externally TOTAL Gross value At January 1, 2020 5,143 9,325 4,500 3,300 22,268 Currency translation adjustments (9 ) (2 ) (11 ) Gross value at December 31, 2020 5,134 9,323 4,500 3,300 22,257 Accumulated amortization and impairment At January 1, 2020 (4,404 ) (5,332 ) (1,963 ) (3,300 ) (14,999 ) Additions (274 ) (1,206 ) (450 ) (1,930 ) Impairment (273 ) (273 ) Currency translation adjustments 2 1 3 Accumulated amortization and impairment at December 31, 2020 (4,676 ) (6,810 ) (2,413 ) (3,300 ) (17,199 ) Net value at December 31, 2020 458 2,513 2,087 0 5,058 Gross value At January 1, 2021 5,134 9,323 4,500 3,300 22,257 Gross value at December 31, 2021 5,134 9,323 4,500 3,300 22,257 Accumulated amortization and impairment At January 1, 2021 (4,676 ) (6,810 ) (2,413 ) (3,300 ) (17,199 ) Additions (234 ) (926 ) (450 ) (1,610 ) Accumulated amortization and impairment at December 31, 2021 (4,910 ) (7,736 ) (2,863 ) (3,300 ) (18,809 ) Net value at December 31, 2021 224 1,587 1,637 0 3,448

Property, Plant and Equipment_2

Property, Plant and Equipment and Right of-Use Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of property, plant and equipment [text block] [Abstract]
Schedule of additional right of use assets	Thousands of $ Laboratory Furniture IT Leasehold TOTAL Gross value At January 1, 2020 5,256 270 333 563 6,422 Additions 101 163 178 98 540 Disposals (4 ) (4 ) Exchange rate difference arising 2 1 (3 ) 5 5 Gross value at December 31, 2020 5,359 434 504 666 6,963 Accumulated depreciation At January 1, 2020 (4,398 ) (211 ) (272 ) (474 ) (5,355 ) Additions (467 ) (34 ) (77 ) (53 ) (631 ) Disposals 1 4 5 Exchange rate difference arising (10 ) 1 2 (2 ) (9 ) Accumulated depreciation at December 31, 2020 (4,874 ) (244 ) (343 ) (529 ) (5,990 ) Net value at December 31, 2020 485 190 161 137 973 Gross value At January 1, 2021 5,359 434 504 666 6,963 Additions 255 131 158 675 1,219 Disposals (2 ) (2 ) Exchange rate difference arising (329 ) 4 13 (312 ) Gross value at December 31, 2021 5,285 569 673 1,341 7,868 Accumulated depreciation At January 1, 2021 (4,874 ) (244 ) (343 ) (529 ) (5,990 ) Additions (277 ) (64 ) (103 ) (77 ) (521 ) Disposals 2 2 Exchange rate difference arising 334 (7 ) (15 ) 312 Accumulated depreciation at December 31, 2021 (4,817 ) (315 ) (459 ) (606 ) (6,197 ) Net value at December 31, 2021 468 254 214 735 1,671
Schedule of right-of-use assets	Thousands of $ Buildings Vehicles Materials TOTAL Gross value At January 1, 2020 1,595 138 897 2,630 Additions 2,017 114 2,131 Disposals (34 ) (34 ) Gross value at December 31, 2020 3,612 218 897 4,727 Accumulated depreciation At January 1, 2020 (577 ) (55 ) (613 ) (1,245 ) Additions (600 ) (55 ) (116 ) (771 ) Disposals 23 23 Accumulated amortization at December 31, 2020 (1,177 ) (87 ) (729 ) (1,993 ) Net value at December 31, 2020 2,435 131 168 2,734 Gross value At January 1, 2021 3,612 218 897 4,727 Additions 1,518 1,518 Disposals Gross value at December 31, 2021 5,130 218 897 6,245 Accumulated depreciation At January 1, 2021 (1,177 ) (87 ) (729 ) (1,993 ) Additions (752 ) (42 ) (111 ) (905 ) Accumulated amortization at December 31, 2021 (1,929 ) (129 ) (840 ) (2,898 ) Net value at December 31, 2021 3,201 89 57 3,347
Schedule of amounts related to leases are recognized in profit & loss	Thousands of $ 2021 2020 2019 Depreciation expense 905 771 751 Interest expense on lease liabilities 229 93 88

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of inventories [text block] [Abstract]
Schedule of inventories	Thousands of $ 2021 2020 Raw materials and consumables 1,911 2,324 Total Inventories 1,911 2,324

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other receivables [text block] [Abstract]
Schedule of trade receivables	Thousands of $ 2021 2020 Trade receivables 4,582 3,771 Total trade receivables 4,582 3,771
Schedule of total accounts receivable balance with the claim date	A/R by claim date Months Thousands of $ 1-3 months 4-6 months 7-12 months Not due Total ConfirmMDx 1,570 716 1,034 3,320 SelectMDx 80 62 115 59 316 Other 114 2 2 17 135 Total Trade Receivables 1,764 780 1,151 76 3,771 A/R by claim date Months Thousands of $ 1-3 months 4-6 months 7-12 months Not due Total ConfirmMDx 1,644 746 1,256 3,646 SelectMDx 151 203 206 33 593 Other 321 22 343 Total Trade Receivables 2,116 949 1,462 55 4,582
Schedule of prepaid expenses and other current assets	Thousands of $ 2021 2020 Prepayments 1,022 868 Deposits 89 52 Recoverable VAT 246 123 Grants to be received 235 0 Other 23 0 Total prepaid expenses and other current assets 1,615 1,043

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of restricted cash and cash equivalents [text block] [Abstract]
Schedule of cash and cash equivalents	Thousands of $ 2021 2020 Cash and cash equivalents 58,498 15,953 Total cash and cash equivalents 58,498 15,953

Loans, Borrowings, Leases obl_2

Loans, Borrowings, Leases obligations and other financial liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Loans Borrowings And Lease Liabilities [Abstract]
Schedule of Loans, Borrowings & Lease liabilities	Thousands of $ 2021 2020 Non-current loans and borrowings Loans (*) 7,490 10,279 Convertible loans 161 0 Lease liabilities (**) 2,624 2,017 Total non-current loans and borrowings 10,275 12,296 Thousands of $ 2021 2020 Current loans and borrowings Loans 4,170 2,818 Convertible loans 271 0 Lease liabilities 840 757 Total current loans and borrowings 5,281 3,575
Schedule of maturity of loans and borrowings	Thousands of $ 2021 2020 Loans (including convertible loan) Within one year 4,780 3,644 Years two to five 9,283 11,736 Leases Within one year 1,127 1,040 Years two to five 3,094 2,414
Schedule of financial instrument related to the initial drawdown fee	Thousands of $ 2021 2020 Other financial liabilities Other non-current financial liabilities 1 1,466 690 Other current financial liabilities 961 909 Total other financial liabilities 2,427 1,599
Schedule of cash and non-cash movements of loans and borrowings	Thousands of Loans and Borrowings Other financial liabilities For the years ended December 31 2021 2020 2021 2020 Beginning balance 13,097 9,617 1,599 1,599 Cash movements Loans and borrowings repaid 2 (39 ) Loans and borrowings received 2,316 Non-cash movements Reclassification 3 (773 ) 773 Effective interest rate adjustment 536 258 194 118 Foreign exchange rate impact / other (768 ) 941 (59 ) Fair value changes through profit and loss 4 (80 ) (118 ) Ending balance 12,092 13,097 2,427 1,599
Schedule of lease liabilities	Thousands of $ Lease liabilities For the years ended December 31 2021 2020 Opening balance 2,774 1,385 Cash movements Repayment of lease liabilities (1,057 ) (831 ) Non-cash movements Interest accretion 229 89 New leases 1,518 2,131 Closing balance 3,464 2,774

Contractual Obligations (Tables

Contractual Obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Contractual Obligations [Abstract]
Schedule of contractual obligations	Thousands of $ 2021 2020 Outstanding commitments for future minimum rent payments, which fall due as follows: Less than one year 215 113 Years 2-5 39 112 Total contractual obligations 254 225

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other payables [text block] [Abstract]
Schedule of trade accounts payable	Thousands of $ 2021 2020 Trade accounts payable 3,192 2,903 Accruals for invoices to be received 4,263 2,417 Total trade accounts payable 7,455 5,320
Schedule of other current liabilities	Thousands of $ 2021 2020 Payroll 2,703 2,539 Other accruals 32 678 Total other current liabilities 2,735 3,217

Financial Instruments and Fai_2

Financial Instruments and Fair Value (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of financial instruments designated at fair value through profit or loss [text block] [Abstract]
Schedule of reconciliation of cash and non-cash movements	Thousands of $ 2021 2020 Fair value Assets At amortized cost Trade receivables 4,582 3,771 Cash and cash equivalents 58,498 15,953 Total financial assets 63,080 19,724 Liabilities At fair value: Other financial liabilities 1,617 1,599 Level 3 Derivative financial liability for Kreos drawdown fee 810 Level 3 Subtotal financial liabilities at fair value 2,427 1,599 At amortized cost: Loans and borrowings 12,092 13,097 Level 2 Lease liabilities 3,464 2,774 Trade payables 7,455 5,320 Subtotal financial liabilities at amortized cost 23,011 21,191 Total financial liabilities 25,438 22,790
Schedule of reconciliation of cash and non-cash movements	Thousands of $ Financial Derivative Instrument Contingent Liability For the years ended December 31 2021 2020 2021 2020 Beginning balance 0 0 1,599 1,599 Cash movements Loans and borrowings repaid Loans and borrowings received Non-cash movements Reclassification (1) 773 Effective interest rate adjustment 194 118 Foreign exchange rate impact / other movements (59 ) Fair value changes through profit and loss 96 (176 ) (118 ) Ending balance 810 0 1,617 1,599

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of earnings per share [text block] [Abstract]
Schedule of basic loss per share to shareholders weighted average number of shares outstanding	Years ended December 31 2021 2020 2019 Loss for the year, in thousands of $ (29,002 ) (28,662 ) (43,100 ) Basic and diluted loss per share, in $ (0.24 ) (0.34 ) (0.69 ) Weighted average number of shares 2021 2020 2019 Weighted average number of shares for basic and diluted loss per share 121,935,741 83,199,215 62,579,345

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of financial risk management [text block] [Abstract]
Schedule of maturity profiles of financial assets and liabilities	For the years ended December 31, 2021 Less than between between Total Carrying Non derivatives Trade payables 7,455 7,455 7,455 Loans 4,780 8,200 1,083 14,063 12,092 Lease liabilities 1,127 915 2,179 4,221 3,464 Total 13,362 9,115 3,262 25,739 23,011 For the years ended December 31, 2020 Less than between between Total Carrying Non derivatives Trade payables 5,320 5,320 5,320 Loans (incl. convertible loan) 3,644 5,568 6,168 15,380 13,097 Lease liabilities 1,040 670 1,744 3,454 2,774 Total 10,004 6,238 7,912 24,154 21,191

Share Capital and Reserves (Tab

Share Capital and Reserves (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of share capital, reserves and other equity interest [text block] [Abstract]
Schedule of share capital number of shares	For the years ended December 31 2021 2020 Common shares 155,969,226 90,691,449 Total outstanding shares 155,969,226 90,691,449
Schedule of share capital and issuance premium increased	Thousands of $/ Thousands of €/ For the years ended December 31 Share Issuance Share Issuance As of January 1, 2020 62,841 136,349 49,754 112,078 May 2020 – Issuance of 20,162,924 shares (*) 13,875 0 12,460 0 As of December 31st, 2020 76,716 136,349 62,214 112,078 January 2021 – Issuance of 27,777,777 shares (*) 23,632 4,693 19,473 3,867 November 2021 – Issuance of 37,500,000 shares (*) 28,106 12,135 24,412 10,536 As of December 31st, 2021 128,454 153,177 106,099 126,481
Schedule of capital stock and the issuance premium	Thousands of $/ Thousands of €/ For the years ended December 31 2021 2020 2021 2020 Share Capital as per statutory accounts 143,419 84,903 118,662 68,999 Capital increase costs (14,965 ) (8,187 ) (12,564 ) (6,785 ) Share capital under IFRS 128,454 76,716 106,098 62,214 Issuance premium 153,177 136,349 126,481 112,078 Share capital and issuance premium 281,631 213,065 232,579 174,292

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Schedule of potential shares from outstanding warrants	Number of potential shares from outstanding warrants 2021 2020 As of January 1 5,766,093 4,250,687 Number of warrants cancelled/forfeited during the year (304,968 ) (357,594 ) Number of warrants granted during the year 3,456,500 1,873,000 As of December 31 8,917,625 5,766,093
Schedule of outstanding warrants and their exercise price	Warrants Weighted average Potential shares Weighted average Granted in 2020 1,873,000 0.81 1,873,000 0.81 Outstanding 31 December 2020 5,766,093 1.74 5,766,093 1 74 Granted in 2021 3,456,500 1.37 3,456,500 1.37 Outstanding 31 December 2021 8,917,625 1.53 8,917,625 1.53 Exercisable at 31 December 2021 3,093,499 2.08 3,093,499 2.08
Schedule of the outstanding potential shares from warrants	Category 2021 2020 Executive Director 2,950,000 1,950,000 Non-Executive Directors 272,000 272,000 Management team (excluding the Executive Director) 2,938,000 1,738,000 Other employees, consultants, and former service providers 2,757,625 1,806,093 Total outstanding at December 31 8,917,625 5,766,093
Schedule of share-based compensation expense recognized in the statement of comprehensive income	Thousands of $ 2021 2020 2019 Share-based compensation 1,222 1,295 872 Cumulated Share-based compensation 10,607 9,385 8,090
Schedule of fair value of each warrant is estimated on the date of grant using the Black-Scholes methodology	Number of warrants granted Expected duration (months) Dates to to Exercise expected Expected Risk-free to to 15-Mar-12 75,000 120,000 € 1.72 - 67.74 % 3.43 % 78.57 60.56 15-Aug-12 12,000 24,000 € 1.52 - 54.50 % 2.57 % 73.54 61.54 14-Sep-12 - 85,000 € 1.65 - 55.58 % 2.59 % 72.56 60.56 01-Dec-12 - 10,000 € 2.19 - 57.13 % 2.19 % 75.98 57.99 01-Jan-13 65,000 107,000 € 2.00 - 57.13 % 2.09 % 80.97 62.92 01-May-13 - 15,000 € 2.13 - 49.75 % 1.93 % 77.03 58.98 31-May-13 12,000 18,000 € 2.05 - 49.62 % 2.22 % 76.04 57.99 12-Mar-14 76,000 177,000 € 3.60 - 47.75 % 2.24 % 72.69 54.67 01-Apr-14 - 12,000 € 4.32 - 48.82 % 2.21 % 72.03 54.02 30-May-14 18,000 18,000 € 4.25 - 48.68 % 1.86 % 70.09 52.08 23-Jun-14 12,000 12,000 € 4.13 - 48.12 % 1.78 % 75.32 63.29 9-Feb-15 60,000 95,000 € 4.49 - 46.75 % 0.62 % 79.73 61.71 29-May-15 20,000 30,000 € 4.91 - 46.52 % 0.81 % 64.14 52.11 1-Oct-15 - 83,000 € 4.20 - 48.99 % 0.90 % 72.03 54.02 1-Dec-15 - 18,000 € 3.89 - 51.18 % 0.85 % 70.03 52.01 1-Feb-16 - 10,000 € 4.13 - 51.18 % 0.85 % 67.99 49.97 4-Feb-16 50,000 134,000 € 3.78 - 52.49 % 0.72 % 67.89 49.87 2-Apr-16 - 52,000 € 3.62 - 53.40 % 0.58 % 65.33 53.33 29-May-16 30,000 40,000 € 4.13 - 51.85 % 0.54 % 64.11 52.11 22-Jan-16 - 20,000 € 3.83 - 52.81 % 0.86 % 68.32 56.32 1-Dec-16 - 22,000 € 4.65 - 54.16 % 0.75 % 57.99 39.98 1-Jan-17 - 19,000 € 4.56 - 53.84 % 0.73 % 56.98 50.96 1-Apr-17 - 18,000 € 5.41 - 51.80 % 0.81 % 54.02 48.00 11-Apr-17 20,000 200,000 € 5.35 - 51.83 % 0.72 % 65.68 47.67 29-Jul-17 - 10,000 € 4.72 - 50.95 % 0.87 % 50.10 44.05 1-Sep-17 - 34,000 € 4.92 - 48.08 % 0.71 % 60.99 42.97 2-Nov-17 - 99,000 € 4.61 - 45.23 % 0.66 % 52.93 40.90 20-Jun-17 30,000 30,000 € 4.97 - 51,57 % 0.59 % 81.40 63.39 01-Apr-18 - 42,000 € 3,77 - 46.08 % 0.76 % 54.02 42.02 01-Jun-18 50,000 30,000 € 4,97 - 46.15 % 0.77 % 52.01 40.01 01-Jun-18 - 8,000 € 3,66 - 44.04 % 0.73 % 48.99 36.99 05-Dec-18 - 20,000 € 1,73 - 57.56 % 0.79 % 45.86 33.86 24-Jan-19 - 191,000 € 1,64 - 67.56 % 0.77 % 62.24 50.20 16-May-19 - 1,508,000 € 1,49 - 75.78 % 0.38 % 58.55 46.52 01-Nov-19 - 8,000 € 1,01 - 82.15 % 0.00 % 64.99 46.98 01-Dec-19 - 12,000 € 1,02 - 81.95 % 0.00 % 64.01 45.99 01-Jan-20 - 6,000 € 1,02 - 81.00 % 0.00 % 62.99 50.99 01-Feb-20 - 2,000 € 0,98 - 80.26 % 0.00 % 61.97 49.67 01-Mar-20 - 4,000 € 0,89 - 80.59 % 0.00 % 61.02 49.02 01-Jun-20 - 6,000 € 0,85 - 86.64 % 0.00 % 57.99 45.99 01-Oct-20 - 2,000 € 0,80 - 85.20 % 0.00 % 53.95 35.97 15-Jul-20 - 225,000 € 0,80 - 85.89 % 0.00 % 56.51 38.53 01-Jul-19 60,000 20,000 € 1,28 - 78.70 % 0.07 % 69.01 51.02 24-Jul-19 - 980,000 € 1,24 - 78.64 % 0.00 % 68.25 50.27 15-Jul-20 - 1,598,000 € 0,80 - 85.89 % 0.00 % 56.52 38.53 30-Jul-20 20,000 - € 1,28 - 87.02 % 0.00 % 56.02 38.04 01-Oct-20 - 10,000 € 1,28 - 85.20 % 0.00 % 53.95 35.97 01-Mar-21 - 2,000 € 1.08 - 65.06 % 0.00 % 48.99 31.00 03-May-21 - 8,000 € 1.16 - 64.59 % 0.01 % 46.92 28.93 01-Jun-21 - 4,000 € 1.18 - 65.82 % 0.01 % 45.96 27.98 27-Jul-21 - 30,000 € 1.36 - 63.36 % 0.00 % 44.12 26.14 27-Jul-21 - 202,500 € 1.36 - 63.36 % 0.00 % 44.12 26.14 24-Nov-21 - 40,000 € 1.05 - 60.78 % 0.14 % 49.25 37.25 03-Jul-21 - 2,570,000 € 1.38 - 63.10 % 0.04 % 44.91 26.93 07-Jul-21 - 600,000 € 1.39 - 63.11 % 0.00 % 44.78 26.79

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of related party [text block] [Abstract]
Schedule of combined remuneration package, including employer taxes	Thousands of $/ except per personnel, warrants & For the years ended December 31 2021 2020 2019 Number of management members and Executive Directors 4 4 4 Short-term employee benefits 1,545 1,535 1,101 Post-employment benefits 52 23 26 Other employment costs 207 174 65 Termination benefits 0 0 1,111 Total benefits 1,804 1,732 2,303 IFRS share-based compensation expense 982 596 34 Number of warrants offered 2,200,000 1,183,000 2,330,000 Cumulative outstanding warrants 5,888,000 3,688,000 2,505,000 Exercisable warrants 1,282,238 1,036,250 160,000
Schedule of number of warrants that were exercised	2021 2020 2019 Number of warrants exercised 0 0 0 Number of new warrants granted and accepted 2,200,000 1,183,000 2,330,000 Annualized IFRS cost for existing warrants $ 982,000 $ 596,000 $ 34,000

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2021
Description of accounting policy for subsidiaries [text block] [Abstract]
Schedule of wholly-owned direct subsidiaries	MDxHealth Inc. Address 15279 Alton Parkway – Suite 100 – Irvine, CA 92618 Incorporation Date April 14, 2003 Number of employees 176 at December 31,2021, 163 at December 31, 2020 and 158 at December 31, 2019. MDxHealth B.V. Address Transistorweg 5, 6534 AT Nijmegen, The Netherlands Incorporation Date October 18, 2006 Incorporated into MDxHealth on September 18, 2015 Number of employees 11 at December 31, 2021, 9 at December 31, 2020 and 11 at December 31, 2019.

Principal Audit Fees and Serv_2

Principal Audit Fees and Services (Tables)	12 Months Ended
	Dec. 31, 2021
Principal Audit Fees And Services [Abstract]
Schedule of statutory auditor performed additional activities	in thousands of $ in thousands of € For the years ended December 31 2021 2020 2019 2021 2020 2019 Audit fee for statutory and consolidated financials 182,125 85,000 111,000 155,000 75,000 99,000 Audit related and other services (IPO in the USA) 200,221 10,000 14,000 170,401 8,000 12,000 Total 382,346 95,000 125,000 325,401 83,000 111,000

Status and Principal Activity (

Status and Principal Activity (Details)	Dec. 31, 2021ft²
Status and principal activity [Abstract]
College of american pathologists	13,448

Summary of Significant Accoun_2

Summary of Significant Accounting policies (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)
Disclosure of significant accounting policies [text block] [Abstract]
Accumulated deficit	$ 244,300,000
Net loss	29,000,000
Net cash used in operating activities	22,500,000
Cash and cash equivalents	58,500,000
Carried forward amount	305,022,000
Net loss carried forward amount		$ 276,166,000	$ 279,752,000
Deferred tax	76,255,500
Deferred tax asset	76,256,000	$ 69,041,000	$ 82,751,000
Financial liability	713,538			€ 630,000
Office equipment	$ 5,000
Weighted values	150.00%

Revenue and Cost of Goods & S_3

Revenue and Cost of Goods & Services Sold (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue and Cost of Goods & Services Sold (Details) [Line Items]
Total Revenues (in Dollars)	$ 22,239,000	$ 18,460,000	$ 11,785,000
Insurance revenue percentage	20.00%
Revenues (in Dollars)			10,078,000
Concluded agreements, description	the Company had concluded agreements with 119 payors for ConfirmMDx (2020: 107; 2019: 90) and 54 payors for SelectMDx (2020: 42; 2019: 32). In 2018 Medicare established a Final Positive Local Coverage Determination for use of ConfirmMDx for Prostate Cancer.
Segment revenue, description	the Company earned 98.6% (2020: 97.9%; 2019: 100%) of its revenue from external customers from its clinical laboratory testing services and out-licensing of intellectual property. In 2021, the clinical laboratory testing in the U.S. CLIA laboratory represented 97% of the Company’s revenue (2020: 95%; 2019: 95%), while the out-licensing of intellectual property revenue in Europe represented 1.5% (2020: 3%; 2019: 5%).
Customer generating over	38.00%
Medicare represented generating of total revenues (in Dollars)	$ 8,509,733	$ 8,805,000	$ 9,701,928
Non-current assets percentage	38.00%	40.00%	52.00%
Europe [Member]
Revenue and Cost of Goods & Services Sold (Details) [Line Items]
Non-current assets percentage	62.00%	60.00%	48.00%
ConfirmMDx [Member]
Revenue and Cost of Goods & Services Sold (Details) [Line Items]
Total Revenues (in Dollars)		$ 18,460,000
Insurance revenue percentage	91.00%	94.00%

Revenue and Cost of Goods & S_4

Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue [Line Items]
Total revenue	$ 22,239	$ 18,460	$ 11,785
Services [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue [Line Items]
Total revenue	21,937	18,064	11,443
Licenses [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue [Line Items]
Total revenue	250	250	250
Royalties [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue [Line Items]
Total revenue	$ 52	$ 146	$ 92

Revenue and Cost of Goods & S_5

Revenue and Cost of Goods & Services Sold (Details) - Schedule of billable test volume by product - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ConfirmMDx [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of billable test volume by product [Line Items]
Product	$ 15,324	$ 14,945	$ 18,195
Product Change Percentage		3.00%	(18.00%)
SelectMDx [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of billable test volume by product [Line Items]
Product	$ 13,615	$ 13,201	$ 21,699
Product Change Percentage		3.00%	(39.00%)

Revenue and Cost of Goods & S_6

Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	$ 22,239,000	$ 18,460,000	$ 11,785,000
United States of America [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	21,785,000	17,760,000	10,878,000
The Netherlands [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	195,000	352,000	339,000
Belgium [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	26,000	29,000	32,000
Spain [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	110,000	132,000	194,000
Poland [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	23,000	16,000	38,000
Italy [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	15,000	38,000	43,000
Rest of EU [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	72,000	112,000	197,000
Rest of the world [Member]
Revenue and Cost of Goods & Services Sold (Details) - Schedule of revenue from external customers broken down by location [Line Items]
Total segment revenue	$ 13,000	$ 21,000	$ 64,000

Revenue and Cost of Goods & S_7

Revenue and Cost of Goods & Services Sold (Details) - Schedule of cost of goods & services sold - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of cost of goods & services sold [Abstract]
Cost of goods & services sold	$ 11,675	$ 10,416	$ 11,755
Total cost of goods & services sold	$ 11,675	$ 10,416	$ 11,755

Nature of Expenses (Details)

Nature of Expenses (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Disclosure of expenses by nature [text block] [Abstract]
Selling and marketing expense	$ 842,000
General and administrative expense, description	A change in presentation for patent expenses has been brought in 2020 to report patent expenses under Research and Development, previously under General and Administrative expenses.

Nature of Expenses (Details) -

Nature of Expenses (Details) - Schedule of research and development expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of research and development expenses [Abstract]
Personnel costs	$ 1,949	$ 1,277	$ 1,143
Depreciation and amortization	1,360	1,203	1,283
Impairment	0	273	5,147
Lab consumables	793	390	480
Patent expenses	577	396	0
External research and development collaborator fees	1,020	874	880
Clinical validation	842	0	0
Other expenses	132	130	64
Total research and development expenses	$ 6,673	$ 4,543	$ 8,997

Nature of Expenses (Details) _2

Nature of Expenses (Details) - Schedule of selling and marketing expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of selling and marketing expenses [Abstract]
Personnel costs	$ 13,402	$ 12,839	$ 12,125
Depreciation	796	603	562
Professional fees	523	497	255
Marketing expenses	1,761	1,315	2,664
Travel expenses	340	260	837
Offices & facilities expenses	436	503	439
Clinical validation	0	377	546
Other expenses	486	358	381
Total selling and marketing expenses	$ 17,744	$ 16,752	$ 17,809

Nature of Expenses (Details) _3

Nature of Expenses (Details) - Schedule of general and administrative expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of general and administrative expenses [Abstract]
Personnel costs	$ 9,009	$ 9,209	$ 8,465
Depreciation and amortization	880	1,526	1,575
Professional fees	2,018	1,522	2,538
Offices & facilities expenses	845	530	537
Royalties to third parties	152	107	174
Patent expenses	0	0	890
Board fees & expenses	314	238	170
Other expenses	931	858	847
Total general and administrative expenses	$ 14,149	$ 13,990	$ 15,196

Personnel Costs (Details) - Sch

Personnel Costs (Details) - Schedule of personnel costs - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of personnel costs [Abstract]
Management (headcount)	$ 4	$ 4	$ 4
Laboratory staff (headcount)	14	10	12
S&M staff (headcount)	111	109	110
G&A staff (headcount)	62	54	51
Total	191	177	177
Their aggregate remuneration comprised:
Wages and salaries	18,150	17,552	16,343
Social security costs	1,257	1,275	1,411
Pension costs	594	567	638
Health insurance expenses	2,324	2,093	1,882
Share-based compensation	1,222	1,295	872
Other costs	813	543	587
Total personnel costs	$ 24,360	$ 23,325	$ 21,733

Other Operating Income (Expen_3

Other Operating Income (Expense), Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Operating Income (Expense), Net (Details) [Line Items]
Grant income	$ 382,000	$ 88,000
Impaired goodwill balance			$ 1,145,000
Grant income from US department [Member]
Other Operating Income (Expense), Net (Details) [Line Items]
Grant income	659,000
Novio Gendix [Member]
Other Operating Income (Expense), Net (Details) [Line Items]
Grant income	$ 1,000,000

Other Operating Income (Expen_4

Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	$ 1,161	$ 118	$ (1,197)
Grant subsidies – The Netherlands [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	382	0	0
Grant subsidies – USA [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	659	0	0
Fair value adjustments [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	176	118	(48)
Impairment [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	0	0	(1,145)
Other operating income [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	53	0	1
Other operating expenses [Member]
Other Operating Income (Expense), Net (Details) - Schedule of other operating income expenses net [Line Items]
Other operating income (expense), net	$ (109)	$ 0	$ (5)

Finance Income _ (Expenses) (De

Finance Income / (Expenses) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Kreos Capital [Member]
Finance Income / (Expenses) (Details) [Line Items]
Loan facility description	The financial results primarily relate to interest charges for the loan facility with Kreos Capital (as explained in detail in note 14) for a total of $1,566,000 and for the interest charges on the lease liability for $229,000.
Novio Gendix [Member]
Finance Income / (Expenses) (Details) [Line Items]
Acquisition total amount	$ 196,000	$ 118,000	$ 104,000

Finance Income _ (Expenses) (_2

Finance Income / (Expenses) (Details) - Schedule of finance income expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of finance income expenses [Abstract]
Interest income	$ 11	$ 4	$ 10
Interest on loans and leases	(1,875)	(1,227)	(318)
Fair value adjustments	(194)	(118)	(104)
Other financial loss	(103)	(198)	(94)
Net financial results	$ (2,161)	$ (1,539)	$ (506)

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax (Details) [Line Items]
Net tax loss	$ 305,022,000	$ 276,166,000	$ 279,752,000
Deferred tax asset	76,256,000	69,041,000	82,751,000
Tax carry forward amount	$ 84,932,000
Tax carry forward expiration period	7 years
Tax credits	$ 372,000	462,000	422,000
Potential deferred tax asset	7,251,000	$ 7,166,000	$ 12,919,000
Business Combinations [Member]
Income Tax (Details) [Line Items]
Net tax loss	13,400,000
Potential deferred tax asset	$ 3,000,000

Income Tax (Details) - Schedule

Income Tax (Details) - Schedule of tax reconciliation and the impact of unrecognized deferred tax assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of tax reconciliation and the impact of unrecognized deferred tax assets [Abstract]
Loss for the year	$ (29,002)	$ (28,662)	$ (43,100)
Income tax expense	0	0	575
Loss before income tax	(29,002)	(28,662)	(43,675)
Tax using the MDxHealth’s domestic tax rate (25.00 % in 2021, 2020 and 29.58% in 2019)	(7,251)	(7,166)	(12,919)
Effect of unused tax losses not recognized as deferred tax assets	$ (7,251)	$ (7,166)	$ (12,919)

Income Tax (Details) - Schedu_2

Income Tax (Details) - Schedule of tax reconciliation and the impact of unrecognized deferred tax assets (Parentheticals)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of tax reconciliation and the impact of unrecognized deferred tax assets [Abstract]
Domestic tax rate	25.00%	25.00%	29.58%

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [text block] [Abstract]
Remaining amortization period	3 years 7 months 6 days	4 years 7 months 6 days
Amortization period	2 years 2 months 12 days	3 years 2 months 12 days
Research & development expenses (in Dollars)			$ 3,300,000
Capitalized development expenses (in Dollars)			$ 1,847,000
Projected discounted period	10 years
Discount rate	12.16%
Perpetual growth rate	3.00%
Cash generating unit (in Dollars)	$ 3,400,000

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	$ 22,257	$ 22,268
Currency translation adjustments		(11)
Accumulated amortization and impairment	(18,809)	(17,199)
Net value	3,448	5,058
Gross value	22,257	22,257
Intellectual and Property Rights & Software Licenses [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	5,134	5,143
Currency translation adjustments		(9)
Accumulated amortization and impairment	(4,910)	(4,676)
Net value	224	458
Gross value	5,134	5,134
Internally Developed Intangible Assets [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	9,323	9,325
Currency translation adjustments		(2)
Accumulated amortization and impairment	(7,736)	(6,810)
Net value	1,587	2,513
Gross value	9,323	9,323
Externally Acquired Developed Technology [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	4,500	4,500
Accumulated amortization and impairment	(2,863)	(2,413)
Net value	1,637	2,087
Gross value	4,500	4,500
Externally Developed In-Process R&D [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	3,300	3,300
Accumulated amortization and impairment	(3,300)	(3,300)
Net value	0	0
Gross value	3,300	3,300
Accumulated depreciation, amortisation and impairment [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	(17,199)	(14,999)
Additions	(1,610)	(1,930)
Impairment		(273)
Currency translation adjustments		3
Accumulated depreciation, amortisation and impairment [Member] | Intellectual and Property Rights & Software Licenses [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	(4,676)	(4,404)
Additions	(234)	(274)
Currency translation adjustments		2
Accumulated depreciation, amortisation and impairment [Member] | Internally Developed Intangible Assets [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	(6,810)	(5,332)
Additions	(926)	(1,206)
Impairment		(273)
Currency translation adjustments		1
Accumulated depreciation, amortisation and impairment [Member] | Externally Acquired Developed Technology [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	(2,413)	(1,963)
Additions	(450)	(450)
Accumulated depreciation, amortisation and impairment [Member] | Externally Developed In-Process R&D [Member]
Intangible Assets (Details) - Schedule of selling and marketing expenses in the statement of profit or loss [Line Items]
Intangible assets beginning balance	$ (3,300)	$ (3,300)

Property, Plant and Equipment_3

Property, Plant and Equipment and Right of-Use Assets (Details) - ft²	1 Months Ended				12 Months Ended
	Oct. 31, 2021	Sep. 30, 2020	Apr. 30, 2020	Dec. 31, 2019	Dec. 31, 2021
Disclosure of property, plant and equipment [text block] [Abstract]
Office space			8,000	11,000
Lease agreements	5 years	6 years			5 years
Laboratory space	13,000
Second lease agreement description					In October of 2021, the company entered into a 35-month sublease agreement (the “Second Lease Agreement”) for 6,000 additional office space adjacent to the laboratory. Under the terms of the Alton Lease and Second Lease Agreement, rental payments escalate through the term of each agreement and the Company is subject to additional charges for common area maintenance and other costs. The new lease agreements from 2021 represent an additional right of use assets of a total value of $1,518,000.

Property, Plant and Equipment_4

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets [Line Items]
Gross value beginning	$ 6,963	$ 6,422
Gross value ending	7,868	6,963
Accumulated depreciation beginning	(5,990)	(5,355)
Accumulated depreciation ending	(6,197)	(5,990)
Net value	1,671	973
Additions	1,219	540
Disposals	(2)	(4)
Exchange rate difference arising	(312)	5
Additions	(521)	(631)
Disposals	2	5
Exchange rate difference arising	312	(9)
Laboratory Equipment [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets [Line Items]
Gross value beginning	5,359	5,256
Gross value ending	5,285	5,359
Accumulated depreciation beginning	(4,874)	(4,398)
Accumulated depreciation ending	(4,817)	(4,874)
Net value	468	485
Additions	255	101
Exchange rate difference arising	(329)	2
Additions	(277)	(467)
Disposals		1
Exchange rate difference arising	334	(10)
Furniture [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets [Line Items]
Gross value beginning	434	270
Gross value ending	569	434
Accumulated depreciation beginning	(244)	(211)
Accumulated depreciation ending	(315)	(244)
Net value	254	190
Additions	131	163
Exchange rate difference arising	4	1
Additions	(64)	(34)
Exchange rate difference arising	(7)	1
IT Equipment [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets [Line Items]
Gross value beginning	504	333
Gross value ending	673	504
Accumulated depreciation beginning	(343)	(272)
Accumulated depreciation ending	(459)	(343)
Net value	214	161
Additions	158	178
Disposals	(2)	(4)
Exchange rate difference arising	13	(3)
Additions	(103)	(77)
Disposals	2	4
Exchange rate difference arising	(15)	2
Leasehold improvements [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of additional right of use assets [Line Items]
Gross value beginning	666	563
Gross value ending	1,341	666
Accumulated depreciation beginning	(529)	(474)
Accumulated depreciation ending	(606)	(529)
Net value	735	137
Additions	675	98
Exchange rate difference arising		5
Additions	$ (77)	(53)
Exchange rate difference arising		$ (2)

Property, Plant and Equipment_5

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of right-of-use assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2021
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of right-of-use assets [Line Items]
Gross value beginning	$ 4,727	$ 2,630
Gross value ending	6,245	4,727
Accumulated amortization beginning	(1,993)	(1,245)
Accumulated amortization ending	(2,898)	(1,993)
Net value	3,347		$ 2,734
Gross value Additions	1,518	2,131
Gross value Disposals		(34)
Accumulated amortization Additions	(905)	(771)
Accumulated amortization Disposals		23
Buildings [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of right-of-use assets [Line Items]
Gross value beginning	3,612	1,595
Gross value ending	5,130	3,612
Accumulated amortization beginning	(1,177)	(577)
Accumulated amortization ending	(1,929)	(1,177)
Net value	3,201		2,435
Gross value Additions	1,518	2,017
Gross value Disposals
Accumulated amortization Additions	(752)	(600)
Accumulated amortization Disposals
Vehicles [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of right-of-use assets [Line Items]
Gross value beginning	218	138
Gross value ending	218	218
Accumulated amortization beginning	(87)	(55)
Accumulated amortization ending	(129)	(87)
Net value	89		131
Gross value Additions		114
Gross value Disposals		(34)
Accumulated amortization Additions	(42)	(55)
Accumulated amortization Disposals		23
Materials [Member]
Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of right-of-use assets [Line Items]
Gross value beginning	897	897
Gross value ending	897	897
Accumulated amortization beginning	(729)	(613)
Accumulated amortization ending	(840)	(729)
Net value	57		$ 168
Gross value Additions
Gross value Disposals
Accumulated amortization Additions	$ (111)	(116)
Accumulated amortization Disposals

Property, Plant and Equipment_6

Property, Plant and Equipment and Right of-Use Assets (Details) - Schedule of amounts related to leases are recognized in profit & loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of amounts related to leases are recognized in profit & loss [Abstract]
Depreciation expense	$ 905	$ 771	$ 751
Interest expense on lease liabilities	$ 229	$ 93	$ 88

Inventories (Details)

Inventories (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of inventories [text block] [Abstract]
Inventories recognized as expense	$ 3,216,000	$ 2,959,000	$ 3,843,000

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventories - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of inventories [Abstract]
Raw materials and consumables	$ 1,911	$ 2,324
Total Inventories	$ 1,911	$ 2,324

Trade and Other Receivables (De

Trade and Other Receivables (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
ConfirmMDx [Member]
Trade and Other Receivables (Details) [Line Items]
Trade accounts receivable	$ 3,805,000	$ 3,438,000
SelectMDx [Member]
Trade and Other Receivables (Details) [Line Items]
Trade accounts receivable	$ 593,000	$ 316,000

Trade and Other Receivables (_2

Trade and Other Receivables (Details) - Schedule of trade receivables - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of trade receivables [Abstract]
Trade receivables	$ 4,582	$ 3,771
Total trade receivables	$ 4,582	$ 3,771

Trade and Other Receivables (_3

Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	$ 4,582	$ 3,771
Months 1-3 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	2,116	1,764
Months 4-6 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	949	780
Months 7-12 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	1,462	1,151
Not due [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	55	76
ConfirmMDx [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	3,646	3,320
ConfirmMDx [Member] | Months 1-3 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	1,644	1,570
ConfirmMDx [Member] | Months 4-6 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	746	716
ConfirmMDx [Member] | Months 7-12 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	1,256	1,034
SelectMDx [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	593	316
SelectMDx [Member] | Months 1-3 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	151	80
SelectMDx [Member] | Months 4-6 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	203	62
SelectMDx [Member] | Months 7-12 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	206	115
SelectMDx [Member] | Not due [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	33	59
Other [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	343	135
Other [Member] | Months 1-3 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	321	114
Other [Member] | Months 4-6 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables		2
Other [Member] | Months 7-12 months [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables		2
Other [Member] | Not due [Member]
Trade and Other Receivables (Details) - Schedule of total accounts receivable balance with the claim date [Line Items]
Total Trade Receivables	$ 22	$ 17

Trade and Other Receivables (_4

Trade and Other Receivables (Details) - Schedule of prepaid expenses and other current assets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses and other current assets [Abstract]
Prepayments	$ 1,022	$ 868
Deposits	89	52
Recoverable VAT	246	123
Grants to be received	235	0
Other	23	0
Total prepaid expenses and other current assets	$ 1,615	$ 1,043

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of cash and cash equivalents [Abstract]
Cash at bank and in hand	$ 58,498	$ 15,953
Total cash and cash equivalents	$ 58,498	$ 15,953

Loans, Borrowings, Leases obl_3

Loans, Borrowings, Leases obligations and other financial liabilities (Details)	1 Months Ended			12 Months Ended
	Apr. 30, 2020USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)€ / shares	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2021EUR (€)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)
Loans, Borrowings, Leases obligations and other financial liabilities (Details) [Line Items]
Ending balance of financial liability						$ 10,300,000
Drawdown fee		$ 1,105,000	€ 1,000,000	$ 713,538	€ 630,000	713,000
Capital amount										$ 10,200,000	€ 9,000,000
Loan had term										4 years	4 years
End-of-loan fee						$ 80,000	€ 67,500
Convertible debt (in Euro) | €								€ 202,500	€ 180,000
Convertible debt loan (in Euro) | €								€ 9,000,000	€ 9,000,000
Percentage of principal amount of the Initial Convertible Loan				25.00%		25.00%		25.00%	25.00%
End-of-loan fee				$ 80,000	67,500
First discretionary convertible loan				(203,868)	180,000
Second discretionary convertible loan				$ (229,352)	€ 202,500
Interest rate for the loan	1.00%			19.56%				19.56%		95.00%	95.00%
Small business administration	$ 2,316,000
Ordinary share price (in Euro per share) | € / shares					€ 0.85
Initial convertible loan percentage				150.00%	150.00%
Convertible loan repayable percentage				150.00%	150.00%
Fair value of the derivative liability				$ 810,000
Change in fair value description				The total change in fair value in 2021 amounts to ($80,000) and is composed as follows:  ●($176,000) for the NovioGendix contingent liability; and,  ●$96,000 for the Kreos Derivative Instrument	The total change in fair value in 2021 amounts to ($80,000) and is composed as follows:  ●($176,000) for the NovioGendix contingent liability; and,  ●$96,000 for the Kreos Derivative Instrument
Bottom of range [Member]
Loans, Borrowings, Leases obligations and other financial liabilities (Details) [Line Items]
Receive gross proceeds				$ 30,000,000
Top of range [Member]
Loans, Borrowings, Leases obligations and other financial liabilities (Details) [Line Items]
Receive gross proceeds				$ 45,000,000

Loans, Borrowings, Leases obl_4

Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of Loans, Borrowings & Lease liabilities - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Non-current loans and borrowings
Loans	[1]	$ 7,490	$ 10,279
Convertible loans		161	0
Lease liabilities	[2]	2,624	2,017
Total non-current loans and borrowings		10,275	12,296
Current loans and borrowings
Loans		4,170	2,818
Convertible loans		271	0
Lease liabilities		840	757
Total current loans and borrowings		$ 5,281	$ 3,575
[1]	The ending balance of $10.3 million as of December 31, 2020, includes the fair value of the derivative financial liability of the initial drawdown fee for an amount of $713,000 which has been presented separately a long-term derivative financial liability which is discussed below.
[2]	the evolution in the right of use assets is further disclosed in note 10.

Loans, Borrowings, Leases obl_5

Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of maturity of loans and borrowings - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Loans (including convertible loan)
Within one year	$ 4,780	$ 3,644
Years two to five	9,283	11,736
Leases
Within one year	1,127	1,040
Years two to five	$ 3,094	$ 2,414

Loans, Borrowings, Leases obl_6

Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of financial instrument related to the initial drawdown fee - USD ($) $ in Thousands		Dec. 31, 2021	Dec. 31, 2020
Other financial liabilities
Other non-current financial liabilities	[1]	$ 1,466	$ 690
Other current financial liabilities		961	909
Total other financial liabilities		$ 2,427	$ 1,599
[1]	Included in 2021 the fair value of the derivative financial liability of the initial drawdown fee of $810,000 which was presented separately

Loans, Borrowings, Leases obl_7

Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of cash and non-cash movements of loans and borrowings - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Loans And Borrowings [Member]
Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of cash and non-cash movements of loans and borrowings [Line Items]
Beginning balance		$ 13,097	$ 9,617
Cash movements
Loans and borrowings repaid	[1]		(39)
Loans and borrowings received			2,316
Non-cash movements
Reclassification	[2]	(773)
Effective interest rate adjustment		536	258
Foreign exchange rate impact / other		(768)	941
Fair value changes through profit and loss			4
Ending balance		12,092	13,097
Other Financial Liabilities [Member]
Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of cash and non-cash movements of loans and borrowings [Line Items]
Beginning balance		1,599	1,599
Non-cash movements
Reclassification	[2]	773
Effective interest rate adjustment		194	118
Foreign exchange rate impact / other		(59)
Fair value changes through profit and loss		(80)	(118)
Ending balance		$ 2,427	$ 1,599
[1]	The amount includes interest paid on loans and borrowings
[2]	Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately

Loans, Borrowings, Leases obl_8

Loans, Borrowings, Leases obligations and other financial liabilities (Details) - Schedule of lease liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of lease liabilities [Abstract]
Opening balance	$ 2,774	$ 1,385
Cash movements
Repayment of lease liabilities	(1,057)	(831)
Non-cash movements
Interest accretion	229	89
New leases	1,518	2,131
Closing balance	$ 3,464	$ 2,774

Contractual Obligations (Detail

Contractual Obligations (Details)	Dec. 31, 2021USD ($)
Contractual Obligations [Abstract]
Equipment value	$ 5,000

Contractual Obligations (Deta_2

Contractual Obligations (Details) - Schedule of contractual obligations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of contractual obligations [Abstract]
Less than one year	$ 215	$ 113
Years 2-5	39	112
Total contractual obligations	$ 254	$ 225

Trade and Other Payables (Detai

Trade and Other Payables (Details)	1 Months Ended
	Apr. 30, 2020USD ($)
U.S. Department of Health & Human Services [Member]
Trade and Other Payables (Details) [Line Items]
Received funding	$ 659,000

Trade and Other Payables (Det_2

Trade and Other Payables (Details) - Schedule of trade accounts payable - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of trade accounts payable [Abstract]
Trade accounts payable	$ 3,192	$ 2,903
Accruals for invoices to be received	4,263	2,417
Total trade accounts payable	$ 7,455	$ 5,320

Trade and Other Payables (Det_3

Trade and Other Payables (Details) - Schedule of other current liabilities - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other current liabilities [Abstract]
Payroll	$ 2,703	$ 2,539
Other accruals	32	678
Total other current liabilities	$ 2,735	$ 3,217

Financial Instruments and Fai_3

Financial Instruments and Fair Value (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Apr. 30, 2020	Dec. 31, 2019
Financial Instruments and Fair Value (Details) [Line Items]
Interest rate percentage	19.56%	19.56%	1.00%	95.00%
Discount rate percentage	12.16%	12.16%
Fair value measurement (in Dollars)	$ 176,000
Derivative financial liability	$ (713,538)	€ 630,000
PPP Loans [Member]
Financial Instruments and Fair Value (Details) [Line Items]
Interest rate percentage	1.00%	1.00%

Financial Instruments and Fai_4

Financial Instruments and Fair Value (Details) - Schedule of assets and liabilities are considered to have carrying amounts - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
At amortized cost
Trade receivables	$ 4,582	$ 3,771
Cash and cash equivalents	58,498	15,953
Total financial assets	63,080	19,724
At fair value:
Other financial liabilities	$ 1,617	1,599
Other financial liabilities	Level 3
Derivative financial liability for Kreos drawdown fee	$ 810
Derivative financial liability for Kreos drawdown fee	Level 3
Subtotal financial liabilities at fair value	$ 2,427	1,599
At amortized cost:
Loans and borrowings	$ 12,092	13,097
Loans and borrowings	Level 2
Lease liabilities	$ 3,464	2,774
Trade payables	7,455	5,320
Subtotal financial liabilities at amortized cost	23,011	21,191
Total financial liabilities	$ 25,438	$ 22,790

Financial Instruments and Fai_5

Financial Instruments and Fair Value (Details) - Schedule of reconciliation of cash and non-cash movements - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Schedule of reconciliation of cash and non-cash movements [Abstract]
Financial Derivative Instrument,beginning balance		$ 0	$ 0
Contingent Liability,beginning balance		1,599	1,599
Financial Derivative Instrument,cash movements
Cash movements
Financial Derivative Instrument, loans and borrowings repaid
Loans and borrowings repaid
Financial Derivative Instrument, loans and borrowings received
Loans and borrowings received
Financial Derivative Instrument, non-cash movements
Reclassification	[1]	773
Effective interest rate adjustment		194	118
Foreign exchange rate impact / other movements		(59)
Financial Derivative Instrument, fair value changes through profit and loss		96
Fair value changes through profit and loss		(176)	(118)
Non-cash movements
Financial Derivative Instrument, ending balance		810	0
Ending balance		$ 1,617	$ 1,599
[1]	Reclassification of the fair value of the derivative financial liability of the initial drawdown fee to be presented separately

Loss Per Share (Details) - Sche

Loss Per Share (Details) - Schedule of basic loss per share to shareholders weighted average number of shares outstanding - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of basic loss per share to shareholders weighted average number of shares outstanding [Abstract]
Loss for the year	$ (29,002)	$ (28,662)	$ (43,100)
Basic and diluted EPS	$ (0.24)	$ (0.34)	$ (0.69)
Weighted average number of shares for basic and diluted EPS	121,935,741	83,199,215	62,579,345

Financial Risk Management (Deta

Financial Risk Management (Details)	1 Months Ended			12 Months Ended
	Apr. 20, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2021EUR (€)
Financial Risk Management (Details) [Line Items]
Trade accounts receivable | $				$ 4,582,000		$ 3,771,000
Loan agreement term							48 months
Exchange rate				10.00%	10.00%
Revenue | $				$ 22,239,000		18,460,000	$ 11,785,000
Cost of sales | $				$ 11,675,000		$ 10,416,000	$ 11,755,000
Potential loss | €					€ 668,000
Exchange rate						10.00%
Number of loan agreements				2	2
Number of leases				11	11
Potential additional cash				$ (1,070,307)	€ 945,000
Currency Risk [Member]
Financial Risk Management (Details) [Line Items]
Customers				1,000				1,000
Trade accounts receivable | $				$ 4,582,000
Cash and cash equivalents | $				$ 58,498,000
Cash on hand | €								€ 7,195,000
Exchange rate				10.00%	10.00%
Net amount | €					€ 7,037,000
Revenue | €					741,000
Cost of sales | €					7,778,000
Potential gain | €					€ 816,000
Interest Risk [Member]
Financial Risk Management (Details) [Line Items]
Total amount		$ 10,200,000	€ 9,000,000
Interest rate				19.56%				19.56%
Paycheck Protection Program [Member] | Interest Risk [Member]
Financial Risk Management (Details) [Line Items]
Interest rate	1.00%
Loan amount | $	$ 2,316,000

Financial Risk Management (De_2

Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities [Line Items]
Trade payables	$ 7,455	$ 5,320
Loans	12,092	13,097
Lease liabilities	3,464	2,774
Total	23,011	21,191
Less than 1 year [Member]
Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities [Line Items]
Trade payables	7,455	5,320
Loans	4,780	3,644
Lease liabilities	1,127	1,040
Total	13,362	10,004
Total Contractual Cash Flows [Member]
Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities [Line Items]
Trade payables	7,455	5,320
Loans	14,063	15,380
Lease liabilities	4,221	3,454
Total	25,739	24,154
Between 1 and 2 years [Member]
Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities [Line Items]
Loans	8,200	5,568
Lease liabilities	915	670
Total	9,115	6,238
Between 3 and 5 years [Member]
Financial Risk Management (Details) - Schedule of maturity profiles of financial assets and liabilities [Line Items]
Loans	1,083	6,168
Lease liabilities	2,179	1,744
Total	$ 3,262	$ 7,912

Share Capital and Reserves (Det

Share Capital and Reserves (Details) € / shares in Units, $ / shares in Units, $ in Millions	Nov. 08, 2021USD ($)$ / sharesshares	May 15, 2020USD ($)shares	Jan. 21, 2021USD ($)shares	Nov. 08, 2021EUR (€)shares	Jan. 21, 2021EUR (€)€ / sharesshares	May 15, 2020EUR (€)€ / shares
Share Capital and Reserves (Details) [Line Items]
Depositary shares				3,750,000
Price per share | (per share)	$ 12				€ 0.9	€ 0.632
Gross proceeds | $	$ 45
New shares				37,500,000
Gross amounts			$ 30.4		€ 25,000,000
Shares premium			27,777,777		27,777,777
Aggregate amount		$ 13.7				€ 12,700,000
New ordinary shares		20,162,924
Bottom of range [member]
Share Capital and Reserves (Details) [Line Items]
Share capital | €				€ 90,132,067.69	€ 68,998,734.95	56,260,102.01
Issued and outstanding shares	118,469,226		90,691,449
Top of range [member]
Share Capital and Reserves (Details) [Line Items]
Share capital | €				€ 118,662,067.69	€ 90,132,067.69	€ 68,998,734.95
Issued and outstanding shares	155,969,226		118,469,226

Share Capital and Reserves (D_2

Share Capital and Reserves (Details) - Schedule of share capital number of shares - shares	Dec. 31, 2021	Dec. 31, 2020
Schedule of share capital number of shares [Abstract]
Common shares	155,969,226	90,691,449
Total outstanding shares	155,969,226	90,691,449

Share Capital and Reserves (D_3

Share Capital and Reserves (Details) - Schedule of share capital and issuance premium increased € in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)
Schedule of share capital and issuance premium increased [Abstract]
Share capital situation at beginning				$ 62,841	€ 49,754
Issuance premium situation at beginning				136,349	112,078
Share capital situation at ending		$ 128,454	€ 106,099	76,716	62,214
Issuance premium situation at ending		153,177	126,481	136,349	112,078
Share capital issuance shares	[1]	23,632	19,473	13,875	12,460
Issuance premium issuance shares	[1]	4,693	3,867	0	0
Share capital issuance of shares	[1]	23,632	19,473	13,875	12,460
Issuance premium issuance of shares	[1]	4,693	3,867	$ 0	€ 0
Share capital issuance shares | $	[1]	28,106
Issuance premium issuance shares	[1]	12,135	10,536
Share capital issuance of shares | €	[1]		24,412
Issuance premium issuance of shares	[1]	$ 12,135	€ 10,536
[1]	net of expenses

Share Capital and Reserves (D_4

Share Capital and Reserves (Details) - Schedule of share capital and issuance premium increased (Parentheticals) - shares	1 Months Ended
	Nov. 30, 2021	Jan. 31, 2021	May 31, 2020
Schedule of share capital and issuance premium increased [Abstract]
Share capital issuance of shares	37,500,000	27,777,777	20,162,924
Issuance premium issuance of shares	37,500,000	27,777,777	20,162,924

Share Capital and Reserves (D_5

Share Capital and Reserves (Details) - Schedule of capital stock and the issuance premium € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2021EUR (€)	Dec. 31, 2020EUR (€)
Schedule of capital stock and the issuance premium [Abstract]
Share Capital as per statutory accounts	$ 143,419		$ 84,903		€ 118,662	€ 68,999
Capital Increase costs	(14,965)		(8,187)		(12,564)	(6,785)
Share capital under IFRS	128,454	€ 106,098	76,716	€ 62,214
Issuance premium	153,177		136,349		126,481	112,078
Share capital and issuance premium	$ 281,631		$ 213,065		€ 232,579	€ 174,292

Retirement Benefit Schemes (Det

Retirement Benefit Schemes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefit Schemes [Abstract]
Total cost	$ 594,000	$ 567,000

Share-based payments (Details)

Share-based payments (Details) - USD ($)	Mar. 15, 2012	May 27, 2021	Jun. 21, 2019	Jun. 19, 2017	Jun. 23, 2014	Jun. 15, 2012	Dec. 31, 2021
Share-based payments (Details) [Line Items]
Stock option plans for grant to employees	$ 195,000			$ 2,500,000
Stock option plans for grant to directors			$ 3,000,000			$ 700,000
Stock option plans for grant to consultants		$ (3,600,000)			$ 1,500,000
Warrants description							In aggregate 12,310,800 warrants were issued, subject to warrants being granted to and accepted by the beneficiaries. 16,150 of these warrants never allocated have become null and void, resulting in a remaining and outstanding 12,294,650 warrants, (i) 2,250,052 warrants were terminated or lapsed, (ii) 577,123 warrants were exercised, (iii) 8,917,625 warrants were granted but not yet exercised, and (iv) 566,000 warrants were not yet granted by the Company. For the year 2021, 304,968 warrants (2020: 357,594) were terminated or lapsed, no warrants were exercised, and 795,250 warrants (2020: 859,999) were vested. As a result, as at December 31, 2021, there are 8,917,625 warrants outstanding, entitling their holders to subscribe to 8,917,625 shares of the Company.
Warrant term							10 years
Cumulative tranches percentage							25.00%
warrants granted (in Shares)							30,000
Vest in instalments percentage							25.00%
Percentage of first tranche							25.00%
Estimated value							$ 0
Expected volatility term							2 years
Warrants [Member]
Share-based payments (Details) [Line Items]
Warrants outstanding, description							The weighted average exercise price of all outstanding warrants (vested and non-vested warrants; assuming 1 warrant = 1 share) is €1.53 or $ conversion 1.73 at December 31, 2021 (€1,74 or $ conversion 2.14 at December 31, 2020; €2.35 or $ conversion 2.64 at December 31, 2019). The weighted average remaining contractual life of all outstanding warrants at the end of 2021 is 7.18 years (2020: 6.70 years; 2019: 6.74 years).

Share-based payments (Details)

Share-based payments (Details) - Schedule of potential shares from outstanding warrants - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of potential shares from outstanding warrants [Abstract]
Balance opening	5,766,093	4,250,687
Number of warrants cancelled/forfeited during the year	(304,968)	(357,594)
Number of warrants granted during the year	3,456,500	1,873,000
Balance ending	8,917,625	5,766,093

Share-based payments (Details_2

Share-based payments (Details) - Schedule of outstanding warrants and their exercise price - € / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Granted in 2020 [Member]
Share-based payments (Details) - Schedule of outstanding warrants and their exercise price [Line Items]
Outstanding warrants beginning		0.81
Outstanding weighted average exercise price beginning (in Euro per share)		€ 1,873,000
Outstanding potential shares from exercise of warrants beginning		0.81
December 2020 [Member]
Share-based payments (Details) - Schedule of outstanding warrants and their exercise price [Line Items]
Outstanding warrants ending		1.74
Outstanding weighted average exercise price ending (in Euro per share)		€ 5,766,093
Outstanding potential shares from exercise of warrants ending		174
Granted in 2021 [Member]
Share-based payments (Details) - Schedule of outstanding warrants and their exercise price [Line Items]
Outstanding warrants beginning	1.37
Outstanding weighted average exercise price beginning (in Euro per share)	€ 3,456,500
Outstanding potential shares from exercise of warrants beginning	1.37
December 2021 [Member]
Share-based payments (Details) - Schedule of outstanding warrants and their exercise price [Line Items]
Outstanding warrants ending	1.53
Outstanding weighted average exercise price ending (in Euro per share)	€ 8,917,625
Outstanding potential shares from exercise of warrants ending	1.53
December 2021 [Member]
Share-based payments (Details) - Schedule of outstanding warrants and their exercise price [Line Items]
Outstanding warrants exercisable	2.08
Outstanding weighted average exercise price exercisable (in Euro per share)	€ 3,093,499
Outstanding potential shares from exercise of warrants exercisable	2.08

Share-based payments (Details_3

Share-based payments (Details) - Schedule of the outstanding potential shares from warrants - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of the outstanding potential shares from warrants [Abstract]
Executive Director	2,950,000	1,950,000
Non-Executive Directors	272,000	272,000
Management team (excluding the Executive Director)	2,938,000	1,738,000
Other employees, consultants, and former service providers	2,757,625	1,806,093
Total outstanding at December 31	8,917,625	5,766,093

Share-based payments (Details_4

Share-based payments (Details) - Schedule of share-based compensation expense recognized in the statement of comprehensive income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of share-based compensation expense recognized in the statement of comprehensive income [Abstract]
Share-based compensation	$ 1,222	$ 1,295	$ 872
Cumulated Share-based compensation	$ 10,607	$ 9,385	$ 8,090

Share-based payments (Details_5

Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology - 12 months ended Dec. 31, 2021	USD ($)shares	€ / shares
15-Mar-12 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	75,000
Number of warrants granted to other benef.	120,000
Exercise price | € / shares		€ 1.72
expected dividend Yield | $
Expected stock price volatility	67.74%
Risk-free interest rate	3.43%
Expected duration (months)to Belgian benef.	78 months 17 days
Expected duration (months)to other benef.	60 months 17 days
15-Aug-12 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	12,000
Number of warrants granted to other benef.	24,000
Exercise price | € / shares		1.52
expected dividend Yield | $
Expected stock price volatility	54.50%
Risk-free interest rate	2.57%
Expected duration (months)to Belgian benef.	73 months 16 days
Expected duration (months)to other benef.	61 months 16 days
14-Sep-12 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	85,000
Exercise price | € / shares		1.65
expected dividend Yield | $
Expected stock price volatility	55.58%
Risk-free interest rate	2.59%
Expected duration (months)to Belgian benef.	72 months 17 days
Expected duration (months)to other benef.	60 months 17 days
01-Dec-12 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	10,000
Exercise price | € / shares		2.19
expected dividend Yield | $
Expected stock price volatility	57.13%
Risk-free interest rate	2.19%
Expected duration (months)to Belgian benef.	75 months 29 days
Expected duration (months)to other benef.	57 months 30 days
01-Jan-13 [Member
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	65,000
Number of warrants granted to other benef.	107,000
Exercise price | € / shares		2
expected dividend Yield | $
Expected stock price volatility	57.13%
Risk-free interest rate	2.09%
Expected duration (months)to Belgian benef.	80 months 29 days
Expected duration (months)to other benef.	62 months 28 days
01-May-13 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	15,000
Exercise price | € / shares		2.13
expected dividend Yield | $
Expected stock price volatility	49.75%
Risk-free interest rate	1.93%
Expected duration (months)to Belgian benef.	77 months
Expected duration (months)to other benef.	58 months 29 days
31-May-13 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	12,000
Number of warrants granted to other benef.	18,000
Exercise price | € / shares		2.05
expected dividend Yield | $
Expected stock price volatility	49.62%
Risk-free interest rate	2.22%
Expected duration (months)to Belgian benef.	76 months 1 day
Expected duration (months)to other benef.	57 months 30 days
12-Mar-14 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	76,000
Number of warrants granted to other benef.	177,000
Exercise price | € / shares		3.6
expected dividend Yield | $
Expected stock price volatility	47.75%
Risk-free interest rate	2.24%
Expected duration (months)to Belgian benef.	72 months 21 days
Expected duration (months)to other benef.	54 months 20 days
01-Apr-14 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	12,000
Exercise price | € / shares		4.32
expected dividend Yield | $
Expected stock price volatility	48.82%
Risk-free interest rate	2.21%
Expected duration (months)to Belgian benef.	72 months
Expected duration (months)to other benef.	54 months
30-May-14 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	18,000
Number of warrants granted to other benef.	18,000
Exercise price | € / shares		4.25
expected dividend Yield | $
Expected stock price volatility	48.68%
Risk-free interest rate	1.86%
Expected duration (months)to Belgian benef.	70 months 2 days
Expected duration (months)to other benef.	52 months 2 days
23-Jun-14 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	12,000
Number of warrants granted to other benef.	12,000
Exercise price | € / shares		4.13
expected dividend Yield | $
Expected stock price volatility	48.12%
Risk-free interest rate	1.78%
Expected duration (months)to Belgian benef.	75 months 9 days
Expected duration (months)to other benef.	63 months 8 days
9-Feb-15 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	60,000
Number of warrants granted to other benef.	95,000
Exercise price | € / shares		4.49
expected dividend Yield | $
Expected stock price volatility	46.75%
Risk-free interest rate	0.62%
Expected duration (months)to Belgian benef.	79 months 22 days
Expected duration (months)to other benef.	61 months 21 days
29-May-15 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	20,000
Number of warrants granted to other benef.	30,000
Exercise price | € / shares		4.91
Expected stock price volatility	46.52%
Risk-free interest rate	0.81%
Expected duration (months)to Belgian benef.	64 months 4 days
Expected duration (months)to other benef.	52 months 3 days
1-Oct-15 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	83,000
Exercise price | € / shares		4.2
expected dividend Yield | $
Expected stock price volatility	48.99%
Risk-free interest rate	0.90%
Expected duration (months)to Belgian benef.	72 months
Expected duration (months)to other benef.	54 months
1-Dec-15 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	18,000
Exercise price | € / shares		3.89
expected dividend Yield | $
Expected stock price volatility	51.18%
Risk-free interest rate	0.85%
Expected duration (months)to Belgian benef.	70 months
Expected duration (months)to other benef.	52 months
1-Feb-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	10,000
Exercise price | € / shares		4.13
expected dividend Yield | $
Expected stock price volatility	51.18%
Risk-free interest rate	0.85%
Expected duration (months)to Belgian benef.	67 months 30 days
Expected duration (months)to other benef.	49 months 29 days
4-Feb-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	50,000
Number of warrants granted to other benef.	134,000
Exercise price | € / shares		3.78
expected dividend Yield | $
Expected stock price volatility	52.49%
Risk-free interest rate	0.72%
Expected duration (months)to Belgian benef.	67 months 27 days
Expected duration (months)to other benef.	49 months 26 days
2-Apr-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	52,000
Exercise price | € / shares		3.62
expected dividend Yield | $
Expected stock price volatility	53.40%
Risk-free interest rate	0.58%
Expected duration (months)to Belgian benef.	65 months 10 days
Expected duration (months)to other benef.	53 months 10 days
29-May-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	30,000
Number of warrants granted to other benef.	40,000
Exercise price | € / shares		4.13
expected dividend Yield | $
Expected stock price volatility	51.85%
Risk-free interest rate	0.54%
Expected duration (months)to Belgian benef.	64 months 3 days
Expected duration (months)to other benef.	52 months 3 days
22-Jan-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	20,000
Exercise price | € / shares		3.83
expected dividend Yield | $
Expected stock price volatility	52.81%
Risk-free interest rate	0.86%
Expected duration (months)to Belgian benef.	68 months 9 days
Expected duration (months)to other benef.	56 months 9 days
1-Dec-16 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	22,000
Exercise price | € / shares		4.65
expected dividend Yield | $
Expected stock price volatility	54.16%
Risk-free interest rate	0.75%
Expected duration (months)to Belgian benef.	57 months 30 days
Expected duration (months)to other benef.	39 months 29 days
1-Jan-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	19,000
Exercise price | € / shares		4.56
expected dividend Yield | $
Expected stock price volatility	53.84%
Risk-free interest rate	0.73%
Expected duration (months)to Belgian benef.	56 months 29 days
Expected duration (months)to other benef.	50 months 29 days
11-Apr-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	18,000
Exercise price | € / shares		5.41
expected dividend Yield | $
Expected stock price volatility	51.80%
Risk-free interest rate	0.81%
Expected duration (months)to Belgian benef.	54 months
Expected duration (months)to other benef.	48 months
11-Apr-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	20,000
Number of warrants granted to other benef.	200,000
Exercise price | € / shares		5.35
Expected stock price volatility	51.83%
Risk-free interest rate	0.72%
Expected duration (months)to Belgian benef.	65 months 20 days
Expected duration (months)to other benef.	47 months 20 days
29-Jul-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	10,000
Exercise price | € / shares		4.72
expected dividend Yield | $
Expected stock price volatility	50.95%
Risk-free interest rate	0.87%
Expected duration (months)to Belgian benef.	50 months 3 days
Expected duration (months)to other benef.	44 months 1 day
1-Sep-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	34,000
Exercise price | € / shares		4.92
expected dividend Yield | $
Expected stock price volatility	48.08%
Risk-free interest rate	0.71%
Expected duration (months)to Belgian benef.	60 months 30 days
Expected duration (months)to other benef.	42 months 29 days
2-Nov-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	99,000
Exercise price | € / shares		4.61
expected dividend Yield | $
Expected stock price volatility	45.23%
Risk-free interest rate	0.66%
Expected duration (months)to Belgian benef.	52 months 28 days
Expected duration (months)to other benef.	40 months 27 days
20-Jun-17 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	30,000
Number of warrants granted to other benef.	30,000
Exercise price | € / shares		4.97
expected dividend Yield | $
Expected stock price volatility	5157.00%
Risk-free interest rate	0.59%
Expected duration (months)to Belgian benef.	81 months 12 days
Expected duration (months)to other benef.	63 months 11 days
01-Apr-18 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	42,000
Exercise price | € / shares		377
expected dividend Yield | $
Expected stock price volatility	46.08%
Risk-free interest rate	0.76%
Expected duration (months)to Belgian benef.	54 months
Expected duration (months)to other benef.	42 months
01-Jun-18 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	50,000
Number of warrants granted to other benef.	30,000
Exercise price | € / shares		497
expected dividend Yield | $
Expected stock price volatility	46.15%
Risk-free interest rate	0.77%
Expected duration (months)to Belgian benef.	52 months
Expected duration (months)to other benef.	40 months
01-Jun-18 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	8,000
Exercise price | € / shares		366
expected dividend Yield | $
Expected stock price volatility	44.04%
Risk-free interest rate	0.73%
Expected duration (months)to Belgian benef.	48 months 30 days
Expected duration (months)to other benef.	36 months 30 days
05-Dec-18 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	20,000
Exercise price | € / shares		173
expected dividend Yield | $
Expected stock price volatility	57.56%
Risk-free interest rate	0.79%
Expected duration (months)to Belgian benef.	45 months 26 days
Expected duration (months)to other benef.	33 months 26 days
24-Jan-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	191,000
Exercise price | € / shares		164
expected dividend Yield | $
Expected stock price volatility	67.56%
Risk-free interest rate	0.77%
Expected duration (months)to Belgian benef.	62 months 7 days
Expected duration (months)to other benef.	50 months 6 days
16-May-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	1,508,000
Exercise price | € / shares		149
expected dividend Yield | $
Expected stock price volatility	75.78%
Risk-free interest rate	0.38%
Expected duration (months)to Belgian benef.	58 months 16 days
Expected duration (months)to other benef.	46 months 15 days
01-Nov-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	8,000
Exercise price | € / shares		101
expected dividend Yield | $
Expected stock price volatility	82.15%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	64 months 30 days
Expected duration (months)to other benef.	46 months 29 days
01-Dec-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	12,000
Exercise price | € / shares		102
expected dividend Yield | $
Expected stock price volatility	81.95%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	64 months
Expected duration (months)to other benef.	45 months 30 days
01-Jan-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	6,000
Exercise price | € / shares		102
expected dividend Yield | $
Expected stock price volatility	81.00%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	62 months 30 days
Expected duration (months)to other benef.	50 months 30 days
01-Feb-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	2,000
Exercise price | € / shares		98
expected dividend Yield | $
Expected stock price volatility	80.26%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	61 months 29 days
Expected duration (months)to other benef.	49 months 20 days
01-Mar-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	4,000
Exercise price | € / shares		89
expected dividend Yield | $
Expected stock price volatility	80.59%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	61 months
Expected duration (months)to other benef.	49 months
01-Jun-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	6,000
Exercise price | € / shares		85
expected dividend Yield | $
Expected stock price volatility	86.64%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	57 months 30 days
Expected duration (months)to other benef.	45 months 30 days
01-Oct-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	2,000
Exercise price | € / shares		80
expected dividend Yield | $
Expected stock price volatility	85.20%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	53 months 28 days
Expected duration (months)to other benef.	35 months 29 days
15-Jul-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	225,000
Exercise price | € / shares		80
expected dividend Yield | $
Expected stock price volatility	85.89%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	56 months 15 days
Expected duration (months)to other benef.	38 months 16 days
01-Jul-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	60,000
Number of warrants granted to other benef.	20,000
Exercise price | € / shares		128
expected dividend Yield | $
Expected stock price volatility	78.70%
Risk-free interest rate	0.07%
Expected duration (months)to Belgian benef.	69 months
Expected duration (months)to other benef.	51 months
24-Jul-19 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	980,000
Exercise price | € / shares		124
expected dividend Yield | $
Expected stock price volatility	78.64%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	68 months 7 days
Expected duration (months)to other benef.	50 months 8 days
15-Jul-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	1,598,000
Exercise price | € / shares		80
expected dividend Yield | $
Expected stock price volatility	85.89%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	56 months 15 days
Expected duration (months)to other benef.	38 months 16 days
30-Jul-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.	20,000
Number of warrants granted to other benef.
Exercise price | € / shares		128
expected dividend Yield | $
Expected stock price volatility	87.02%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	56 months
Expected duration (months)to other benef.	38 months 1 day
01-Oct-20 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	10,000
Exercise price | € / shares		128
expected dividend Yield | $
Expected stock price volatility	85.20%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	53 months 28 days
Expected duration (months)to other benef.	35 months 29 days
01-Mar-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	2,000
Exercise price | € / shares		1.08
expected dividend Yield | $
Expected stock price volatility	65.06%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	48 months 30 days
Expected duration (months)to other benef.	31 months
03-May-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	8,000
Exercise price | € / shares		1.16
expected dividend Yield | $
Expected stock price volatility	64.59%
Risk-free interest rate	0.01%
Expected duration (months)to Belgian benef.	46 months 28 days
Expected duration (months)to other benef.	28 months 28 days
01-Jun-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	4,000
Exercise price | € / shares		1.18
expected dividend Yield | $
Expected stock price volatility	65.82%
Risk-free interest rate	0.01%
Expected duration (months)to Belgian benef.	45 months 29 days
Expected duration (months)to other benef.	27 months 29 days
27-Jul-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	30,000
Exercise price | € / shares		1.36
expected dividend Yield | $
Expected stock price volatility	63.36%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	44 months 3 days
Expected duration (months)to other benef.	26 months 4 days
27-Jul-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	202,500
Exercise price | € / shares		1.36
expected dividend Yield | $
Expected stock price volatility	63.36%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	44 months 3 days
Expected duration (months)to other benef.	26 months 4 days
24-Nov-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	40,000
Exercise price | € / shares		1.05
expected dividend Yield | $
Expected stock price volatility	60.78%
Risk-free interest rate	0.14%
Expected duration (months)to Belgian benef.	49 months 7 days
Expected duration (months)to other benef.	37 months 7 days
03-Jul-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	2,570,000
Exercise price | € / shares		1.38
expected dividend Yield | $
Expected stock price volatility	63.10%
Risk-free interest rate	0.04%
Expected duration (months)to Belgian benef.	44 months 27 days
Expected duration (months)to other benef.	26 months 28 days
07-Jul-21 [Member]
Share-based payments (Details) - Schedule of fair value of each warrant is estimated on the date of grant using the black-scholes methodology [Line Items]
Number of warrants granted to Belgian benef.
Number of warrants granted to other benef.	600,000
Exercise price | € / shares		€ 1.39
expected dividend Yield | $
Expected stock price volatility	63.11%
Risk-free interest rate	0.00%
Expected duration (months)to Belgian benef.	44 months 23 days
Expected duration (months)to other benef.	26 months 24 days

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of related party [text block] [Abstract]
Total remuneration	$ 863,000	$ 775,000	$ 484,000
Reimbursement expenses	12,000
Reimbursement for expenses	$ 302,000	$ 231,000	$ 135,000
Non-executive directors (in Shares)	20,000

Related Parties (Details) - Sch

Related Parties (Details) - Schedule of combined remuneration package, including employer taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of combined remuneration package, including employer taxes [Abstract]
Number of management members and Executive Directors (in Shares)	4	4	4
Short-term employee benefits	$ 1,545	$ 1,535	$ 1,101
Post-employment benefits	52	23	26
Other employment costs	207	174	65
Termination benefits	0	0	1,111
Total benefits	1,804	1,732	2,303
IFRS share-based compensation expense	$ 982	$ 596	$ 34
Number of warrants offered (in Shares)	2,200,000	1,183,000	2,330,000
Cumulative outstanding warrants	$ 5,888,000	$ 3,688,000	$ 2,505,000
Exercisable warrants	$ 1,282,238	$ 1,036,250	$ 160,000

Related Parties (Details) - S_2

Related Parties (Details) - Schedule of number of warrants that were exercised - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of number of warrants that were exercised [Abstract]
Number of warrants exercised	0	0	0
Number of new warrants granted and accepted	2,200,000	1,183,000	2,330,000
Annualized IFRS cost for existing warrants (in Dollars)	$ 982,000	$ 596,000	$ 34,000

Significant Agreements, Commi_2

Significant Agreements, Commitments and Contingencies (Details)	1 Months Ended		12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 18, 2015EUR (€)€ / sharesshares
Significant Agreements, Commitments and Contingencies (Details) [Line Items]
Common stock shares issued (in Shares) | shares							1,086,956
Common stock, issued price per share (in Euro per share) | € / shares							€ 4.14
Additional cash consideration (in Euro) | €							€ 250,000
Fees paid	$ 1,105,000	€ 1,000,000	$ 713,538	€ 630,000	$ 713,000
Fair value					1,599,000	$ 1,599,000
Maturity fee					$ 2,200,000
Short-term contracts [Member]
Significant Agreements, Commitments and Contingencies (Details) [Line Items]
Agreement years					1 year
Long-term contracts [Member]
Significant Agreements, Commitments and Contingencies (Details) [Line Items]
Agreement years					3 years

Subsidiaries (Details) - Schedu

Subsidiaries (Details) - Schedule of wholly-owned direct subsidiaries	12 Months Ended
	Dec. 31, 2021
MDXHEALTH INC.[Member]
Subsidiaries (Details) - Schedule of wholly-owned direct subsidiaries [Line Items]
Address	15279 Alton Parkway – Suite 100 – Irvine, CA 92618
Incorporation Date	Apr. 14, 2003
Number of employees	176 at December 31,2021, 163 at December 31, 2020 and 158 at December 31, 2019.
MDXHEALTH B.V [Member]
Subsidiaries (Details) - Schedule of wholly-owned direct subsidiaries [Line Items]
Address	Transistorweg 5, 6534 AT Nijmegen, The Netherlands
Incorporation Date	Oct. 18, 2006
Incorporated into MDxHealth on	Sep. 18, 2015
Number of employees	11 at December 31, 2021, 9 at December 31, 2020 and 11 at December 31, 2019.

Principal Audit Fees and Serv_3

Principal Audit Fees and Services (Details) - Schedule of statutory auditor performed additional activities € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2021EUR (€)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)
Schedule of statutory auditor performed additional activities [Abstract]
Audit fee for statutory and consolidated financials	$ 182,125		$ 85,000		$ 111,000		€ 155,000	€ 75,000	€ 99,000
Audit related and other services (IPO in the USA)	200,221	€ 170,401	10,000	€ 8,000	14,000	€ 12,000
Total	$ 382,346	€ 325,401	$ 95,000	€ 83,000	$ 125,000	€ 111,000